Western Midstream to Participate in RBC Midstream and Energy Infrastructure Conference

Announces Third-Quarter Post-Earnings Interview with CEO, Michael Ure

PR Newswire

HOUSTON, Nov. 12, 2020 /PRNewswire/ — Today Western Midstream Partners, LP (NYSE: WES) announced that Michael Ure, President, Chief Executive Officer, and Chief Financial Officer, will participate in a question and answer session at the RBC Capital Markets Midstream and Energy Infrastructure Virtual Conference, on Wednesday, November 18, 2020 at 10:40 a.m. EST. To provide additional insight related to third-quarter results, an interview with Michael Ure will be posted on Western Midstream’s website at www.westernmidstream.com after-market close Tuesday, November 17, 2020.

ABOUT WESTERN MIDSTREAM
Western Midstream Partners, LP (“WES”) is a Delaware master limited partnership formed to acquire, own, develop, and operate midstream assets. With midstream assets located in the Rocky Mountains, North-central Pennsylvania, Texas, and New Mexico, WES is engaged in the business of gathering, compressing, treating, processing, and transporting natural gas; gathering, stabilizing, and transporting condensate, natural-gas liquids, and crude oil; and gathering and disposing of produced water for its customers. In its capacity as a natural-gas processor, WES also buys and sells natural gas, natural-gas liquids, and condensate on behalf of itself and as an agent for its customers under certain contracts.

For more information about Western Midstream Partners, LP, please visit www.westernmidstream.com.

WESTERN MIDSTREAM CONTACTS

Kristen S. Shults

Vice President, Investor Relations and Communications
[email protected] 
832.636.6000

Abby Dempsey

Investor Relations Supervisor
[email protected]
832.636.6000

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/western-midstream-to-participate-in-rbc-midstream-and-energy-infrastructure-conference-301171270.html

SOURCE Western Midstream Partners, LP

Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update

PR Newswire

SEATTLE and VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.


Recent Events & Highlights

  • Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States
  • Promoted John Bencich to Chief Executive Officer and Dr. Cindy Jacobs to President
  • Presented successful results from the RAUORA, head-to-head non-inferiority clinical trial comparing cytisinicline and Chantix® (varenicline), at the Society for Research on Nicotine and Tobacco European (SRNT-E) Annual Meeting
  • Presented mechanism of action data comparing 5-HT3 receptor activity of cytisinicline vs. Chantix at SRNT-E, providing rationale for differentiated side effect profile of smoking cessation treatments
  • Announced smoking cessation Key Opinion Leader Virtual Roundtable to be held on November 17, 2020

“With the initiation of the Phase 3 ORCA-2 trial and the breakthrough evidence, both mechanistically and clinically, in support of cytisinicline in comparison to Chantix, the third quarter of 2020 has undeniably been the most pivotal in the history of our company,” commented John Bencich, Chief Executive Officer of Achieve. “Our primary focus in the coming months will be enrollment and execution of ORCA-2, while continuing to explore opportunities for commercialization and expansion into new therapeutic indications, digital health technologies, and audiences who may benefit from cytisinicline, specifically, users of vapes or e-cigarettes.”


Phase 3 ORCA-2 Trial Initiation

Achieve’s first Phase 3 ORCA-2 trial was initiated in October 2020 and will randomize 750 U.S. smokers to one of three study arms to determine the efficacy and safety of cytisinicline administered for either 6 or 12 weeks, compared to placebo. The primary endpoint is biochemically verified continuous abstinence during the last 4 weeks of treatment in the 6 and 12-week cytisinicline treatment arms compared to placebo.  Each treatment arm will be compared independently to the placebo arm and the trial will be determined to be successful if either or both of the cytisinicline treatment arms show a statistical benefit compared to placebo.


Management Team Update

In September, the Company announced the promotion of John Bencich to Chief Executive Officer and Dr. Cindy Jacobs to President. Mr. Bencich has been serving as Achieve’s Chief Financial and Operating Officer since 2017 and will join the Board of Directors in his role. Dr. Jacobs has been serving as the Chief Medical Officer of Achieve since 2017 and will continue in her role leading the regulatory and clinical development efforts for cytisinicline. Rick Stewart will remain with Achieve as the Executive Chairman of the Board of Directors and Dr. Anthony Clark will remain in his role as Chief Scientific Officer.


RAUORA: Significantly Fewer Adverse Events and Higher Quits Rates for Cytisinicline vs Chanti


x

Final results from the New Zealand RAUORA Phase 3 non-inferiority clinical trial comparing cytisinicline to varenicline (Chantix) in Māori (indigenous New Zealanders) and whānau (family) of Māori were presented at the SRNT-E Annual Meeting in September 2020. Results showed that cytisinicline met the pre-specified non-inferiority endpoint and was trending towards superiority demonstrating a 4.29% improvement in quit rates in favor of cytisinicline. Subjects in the cytisinicline arm were approximately one and a half times more likely to have quit smoking at 6 months compared to subjects who received varenicline. Importantly, significantly fewer overall adverse events (AEs) were reported in cytisinicline-treated subjects. Of the subjects who experienced AEs (111 in the cytisinicline arm compared to 138 in the varenicline arm), there was significantly less nausea and vivid dreams.


MOA Data Explaining Reduced Nausea and Vomiting with Cytisinicline Presented at SRNT-E

Data presented at the SRNT-E Annual Meeting in September 2020 provides a rationale based on detailed receptor pharmacology to explain why the incidence of nausea and vomiting associated with cytisinicline appears to be consistently lower than that seen with Chantix. The preclinical study, conducted at the University of Cambridge Department of Biochemistry, was designed to examine the in vitro binding characteristics of cytisinicline compared to varenicline at the human 5-HT3 receptor. The study reported an IC50 of 0.50 mM for cytisinicline and 0.25 µM for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.


Virtual Smoking Cessation KOL Roundtable to be Held November 17, 2020

Achieve announced plans to host a virtual roundtable on cytisinicline and smoking cessation on Tuesday, November 17, 2020, at 12:00PM EST. Five esteemed experts in the field of smoking cessation will discuss the ongoing ORCA-2 trial, review recent cytisinicline data, and discuss the importance of smoking cessation in the midst of the COVID-19 pandemic. Visit http://ir.achievelifesciences.com/events-and-webcasts for additional information and click here to register for the event.


Financial Results

As of September 30, 2020, the company’s cash, cash equivalents, and restricted cash was $22.4 million. Total operating expenses for the three and nine months ended September 30, 2020 were $3.8 million and $10.0 million, respectively. Total net loss for the three and nine months ended September 30, 2020 was $3.8 million and $10.0 million, respectively.

As of November 12, 2020, Achieve had 3,617,664 shares outstanding.

Conference Call Details
Achieve will host a conference call at 4:30pm Eastern time today, Thursday, November 12, 2020. To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 8047128. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

About Achieve and Cytisinicline  
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.  

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and commercialization activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time to time, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.

Media Contact 
Glenn Silver 
[email protected] 
(646) 871-8485 

Investor Relations Contact 
Jason Wong 
[email protected]  
(415) 375-3340 ext. 4 

References 
World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 
2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.  

Chantix® is a registered trademark of Pfizer Inc.


Consolidated Statements of Loss


(In thousands, except per share and share data)


Three Months Ended September 30,


Nine Months Ended September 30,


2020


2019


2020


2019

Operating expenses:

  Research and development

1,891

1,824

4,535

7,911

  General and administrative

1,863

1,893

5,494

5,408

    Total operating expenses

3,754

3,717

10,029

13,319

Loss from operations

(3,754)

(3,717)

(10,029)

(13,319)

  Other income (expense)

(10)

44

23

118

Net loss

$                         (3,764)

$                         (3,673)

$                       (10,006)

$                       (13,201)

Basic and diluted net loss per share

$                           (1.14)

$                           (9.07)

$                           (4.55)

$                         (35.96)

Weighted average number of basic and diluted common shares

3,289,252

405,012

2,197,368

367,103


Consolidated Balance Sheets


(In thousands)


 September 30, 


 December 31, 


2020


2019

Assets:

  Cash, cash equivalents, short term investments and restricted cash

$                        22,443

$                        16,714

  Prepaid expenses and other current assets

1,669

670

  Property, equipment and other assets

358

244

  Right-of-use assets

193

329

  License agreement

1,920

2,087

  Goodwill

1,034

1,034

Total assets

$                        27,617

$                        21,078

Liabilities and stockholders’ equity:

  Accounts payable and accrued liabilities

$                          1,719

$                          2,666

  Current portion of long-term obligations

129

203

  Long-term obligations

94

159

  Stockholders’ equity

25,675

18,050

Total liabilities and stockholders’ equity

$                        27,617

$                        21,078

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-reports-financial-results-for-third-quarter-2020-and-provides-corporate-and-cytisinicline-development-update-301171373.html

SOURCE Achieve Life Sciences, Inc.

Helius Medical Technologies, Inc. Reports Third Quarter of Fiscal Year 2020 Financial Results

NEWTOWN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2020.


Third


Quarter and Recent Business Updates

  • The Company made a leadership change by appointing Dane C. Andreeff to the position of Interim President and Chief Executive Officer (“CEO”), and Blane Walter as Chairman of the Board of Directors. These moves followed the departure of Philippe Deschamps from his role as President, CEO and Chairman of the Board of Directors.
  • Following the receipt of Breakthrough Designation earlier this year, the Company submitted a request to the U.S. Food and Drug Administration (“FDA”) for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS™) device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (“MS”). The Company received a request for additional information from the FDA which includes requests for additional analysis of clinical data and proposes certain labeling modifications.  
  • Subsequent to quarter-end the Company closed a private placement for total gross proceeds of approximately $3.4 million led by a syndicate consisting of current members of the management team and other current investors which the Company expects will be sufficient to fund our operations throughout most of the first quarter of 2021.
  • The Company expanded its authorized clinic network to a total of 27 Authorized PoNS Treatment™ Clinic locations spanning across Canada, up from 7 clinics at the beginning of the year.
  • The Company announced the publication of an important study, titled Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury, in the peer-reviewed journal, EMJ Radiology.
  • The putative shareholder class action lawsuit against the Company in the Southern District of New York was dismissed without prejudice in July 2020.


Third


Quarter 20


20


Financial Summary

  • Revenue of $131 thousand, compared to revenue of $150 thousand in third quarter of 2019.
  • Operating loss of $3.7 million, compared to operating loss of $5.7 million in third quarter of 2019.
  • Net loss of $3.5 million, compared to net loss of $5.6 million in third quarter of 2019.
  • As of September 30, 2020, the Company had cash of $2.7 million, compared to $5.5 million at December 31, 2019. The Company had no debt outstanding at September 30, 2020.

“I’m very pleased by our team’s performance during the third quarter, especially given the challenging environment created by the COVID pandemic,” said Dane Andreeff, Interim President and Chief Executive Officer of Helius. “We continued to make strong progress in our strategy to obtain regulatory clearance in the U.S. and submitted our request for de novo classification and clearance to the FDA on August 4th. We look forward to working with the FDA within the context of our Breakthrough Device Designation to facilitate the review of our PoNS device, with the goal of making it available to the estimated 1 million U.S. MS patients as quickly as possible. While our sales performance in Canada continued to be impacted by the disruption due to COVID, our commercial team has done an impressive job of engaging and training Canadian clinics to provide PoNS Treatment, expanding our network to a total of 27 PoNS authorized clinics as of last week.”

“Looking ahead, Helius remains committed to driving continued progress with respect to the two primary aspects of our near-term strategy: pursuing regulatory clearance in the U.S. and advancing our commercialization in the Canadian market. By focusing on these priorities, and continuing to operate as efficiently as possible, we believe we are pursuing the best course to benefit our customers, patients and shareholders. We look forward to building on our recent successes and facilitating awareness, accessibility and adoption of our revolutionary PoNS Treatment to bring 2020 to a strong close.”


Third


Quarter


2020


Financial Results

Total revenue for the third quarter of 2020 was $131 thousand, compared to $150 thousand in the third quarter of 2019. Product sales represented approximately 95% of total revenue in the third quarter of 2020 compared to 100% of total revenue in the third quarter of 2019. Product sales in both periods were generated through sales of the PoNS device pursuant to supply agreements with PoNS Authorized clinic locations in Canada. License and fee revenue represented 5% of sales in the third quarter of 2020, compared to 0% of sales in the third quarter of 2019.

Gross profit for the third quarter of 2020 was $109 thousand, compared to gross profit of $61 thousand in the third quarter of 2019. Operating expenses for the third quarter of 2020 decreased $2.0 million, or 35% year-over-year, to $3.8 million, compared to $5.8 million in the third quarter of 2019.

Operating loss for the third quarter of 2020 decreased $2.1 million, or 36% year-over-year, to $3.7 million, compared to $5.7 million in the third quarter of 2019.

Total other income for the third quarter of 2020 was $183 thousand, compared to $148 thousand in the third quarter of 2019.

Net loss for the third quarter of 2020 was $3.5 million, or $(0.08) per basic and diluted common share, compared to a net loss of $5.6 million, or $(0.22) per basic and diluted common share, in the third quarter of 2019. Weighted average shares used to compute basic and diluted net loss per common share were 45.1 million and 25.9 million for the third quarters of 2020 and 2019, respectively.


Nine Months Ended


September 30, 2020


Financial Results

Total revenue for the nine months ended September 30, 2020 was $0.5 million, compared to $1.3 million in the prior year period. Product sales represented 94% of total revenue for the nine months ended September 30, 2020, compared to 96% of total revenue in the prior year period. Product sales in both periods were generated through sales of the PoNS device pursuant to supply agreements with PoNS Authorized clinic locations in Canada. License and fee revenue represented 6% of total revenue for the nine months ended September 30, 2020, compared to 4% of total revenue in the prior year period.

Gross profit for the nine months ended September 30, 2020 was $0.3 million, compared to gross profit of $0.8 million in the prior year period. Operating expenses for the nine months ended September 30, 2020 decreased $7.5 million, or 39% year-over-year, to $11.7 million, compared to $19.2 million in the prior year period.

Operating loss the nine months ended September 30, 2020 decreased $7.0 million, or 38% year-over-year, to $11.4 million, compared to operating loss of $18.4 million in the prior year period.

Total other expense for the nine months ended September 30, 2020 was $211 thousand, compared to $13.9 million of other income in the prior year period. The year-over-year change is driven primarily by the change in fair value of derivative instruments which is primarily attributable to the change in our stock price, volatility and the number of derivative financial instruments being measured during the period.

Net loss for the nine months ended September 30, 2020 was $11.6 million, or $(0.30) per basic and diluted common share, compared to net loss of $4.5 million, or $(0.17) per basic and diluted common share, in the prior year period. Weighted average shares used to compute basic and diluted net loss per share were 39.2 million and 25.9 million for the nine months ended September 30, 2020 and 2019, respectively.

Net cash provided by financing activities during the nine months ended September 30, 2020 was $6.7 million.

As of September 30, 2020, the Company had cash of $2.7 million, compared to $5.5 million at December 31, 2019. The Company had no debt outstanding at September 30, 2020. Subsequent to quarter end, the Company raised $3.4 million of gross proceeds in a private placement, which the Company expects will extend its cash runway throughout most of the first quarter of 2021.


Full Year 20


20


Outlook

On May 7, 2020, the Company withdrew its previously announced full year 2020 outlook. The Company is currently unable to estimate the duration and impact of the COVID-19 pandemic on its financial and operating results for the full year 2020.


Conference Call

Management will host a conference call at 5:45 p.m. Eastern Time on November 12, 2020 to discuss the results of the quarter and business outlook. Those who would like to participate may dial 877-407-2988 (201-389-0923 for international callers) and provide access code 13711025. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website at: https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13711025. The webcast will be archived on the Events section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Treatment

The Portable Neuromodulation Stimulator (PoNS™) is an authorized class II, non-implantable, medical device in Canada intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for de novo classification and clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.

Cautionary Disclaimer Statement: 

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “expect,” “look forward,” “will” and similar expressions. Such forward-looking statements include, among others, statements regarding the COVID-19 pandemic, including its impact on the Company, the Company’s future growth and operational progress, including clinical and regulatory development plans for the PoNS device, the Company’s expectations regarding the sufficiency of funds for anticipated future operations, potential receipt of regulatory clearance of the PoNS device in the United States, the success of the Company’s planned study, business and commercialization initiatives and objectives, and expectations for full year 2020.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the impact of the COVID-19 pandemic, uncertainties associated with clinical trial enrollments and the results of the planned study, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Company’s capital requirements to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.



Helius Medical Technologies, Inc.

Unaudited
Consolida
ted Balance Sheets

(Except for share data, amounts in thousands)

    September 30, 2020     December 31, 2019  
ASSETS                
Current assets                
Cash   $ 2,680     $ 5,459  
Accounts receivable, net     80       210  
Other receivables     138       364  
Inventory, net of reserve     572       598  
Prepaid expenses     666       610  
Total current assets     4,136       7,241  
Property and equipment, net     463       712  
Other assets                
Goodwill     725       1,242  
Intangible assets, net     579       582  
Operating lease right-of-use asset, net     105       552  
Other assets     18       18  
Total other assets     1,427       2,394  
TOTAL ASSETS   $ 6,026     $ 10,347  
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable   $ 720     $ 1,676  
Accrued liabilities     1,399       1,519  
Operating lease liability     107       172  
Derivative financial instruments           5  
Deferred revenue     339       430  
Total current liabilities     2,565       3,802  
Non-current liabilities                
Operating lease liability     47       465  
Deferred revenue     217       245  
TOTAL LIABILITIES     2,829       4,512  
STOCKHOLDERS’ EQUITY                
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2020 and December 31, 2019            
Class A common stock, $0.001 par value; 150,000,000 shares authorized; 45,354,612 and 30,718,554 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively     45       31  
Additional paid-in capital     120,213       111,479  
Accumulated other comprehensive loss     (693 )     (902 )
Accumulated deficit     (116,368 )     (104,773 )
TOTAL STOCKHOLDERS’ EQUITY     3,197       5,835  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 6,026     $ 10,347  



Helius Medical Technologies, Inc.

Unaudited
Consolidated Statements of Operations and Comprehensive
Loss

(Amounts in thousands except
share
and per share data)

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2020     2019     2020     2019  
Revenue:                                
Product sales, net   $ 124     $ 150     $ 441     $ 1,295  
Fee revenue                 9       49  
License revenue     7             20        
Total operating revenue     131       150       470       1,344  
Cost of sales:                                
Cost of product sales     22       89       187       538  
Gross profit     109       61       283       806  
Operating expenses:                                
Research and development     1,327       1,506       3,755       6,462  
Selling, general and administrative     2,370       4,291       7,625       12,715  
Amortization expense     72             287        
Total operating expenses     3,769       5,797       11,667       19,177  
Operating loss     (3,660 )     (5,736 )     (11,384 )     (18,371 )
Other income (expense):                                
Other income           11       63       35  
Change in fair value of derivative financial instruments     1       196       4       14,033  
Foreign exchange gain (loss)     182       (59 )     (278 )     (147 )
Total other income (expense)     183       148       (211 )     13,921  
Net loss     (3,477 )     (5,588 )     (11,595 )     (4,450 )
Other comprehensive loss:                                
Foreign currency translation adjustments     (172 )     68       209       (168 )
Comprehensive loss   $ (3,649 )   $ (5,520 )   $ (11,386 )   $ (4,618 )
Net loss per share                                
Basic   $ (0.08 )   $ (0.22 )   $ (0.30 )   $ (0.17 )
Diluted   $ (0.08 )   $ (0.22 )   $ (0.30 )   $ (0.17 )
Weighted average shares outstanding                                
Basic     45,137,995       25,903,544       39,187,370       25,869,039  
Diluted     45,137,995       25,903,544       39,187,370       25,869,039  



Helius Medical Technologies, Inc.

Unaudited
Condensed Consolidated Statements of Cash Flows

(Amounts in thousands)

    Nine Months Ended  
    September 30,  
    2020     2019  
Cash flows from operating activities:                
Net loss   $ (11,595 )   $ (4,450 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Change in fair value of derivative financial instruments     (4 )     (14,033 )
Stock-based compensation expense     2,021       3,336  
Unrealized foreign exchange loss     245       211  
Depreciation expense     92       89  
Amortization expense     287        
Provision for doubtful accounts     160        
Intangible asset impairment     182        
Loss from disposal of property and equipment     110        
Gain from lease modification     (56 )      
Changes in operating assets and liabilities:                
Accounts receivable     (30 )     (380 )
Other receivables     226       (123 )
Inventory     26       (897 )
Prepaid expenses     (56 )     285  
Other current assets           264  
Operating lease liability     20       (9 )
Accounts payable     (956 )     (678 )
Accrued liabilities     (120 )     (75 )
Deferred revenue     (119 )      
Net cash used in operating activities     (9,567 )     (16,460 )
Cash flows from investing activities:                
Purchase of property and equipment     (14 )     (260 )
Proceeds from sale of property and equipment     61        
Internally developed software     (7 )      
Net cash provided by (used in) investing activities     40       (260 )
Cash flows from financing activities:                
Proceeds from the issuance of common stock and accompanying warrants     7,233        
Share issuance costs     (506 )     (52 )
Proceeds from the exercise of stock options and warrants           215  
Proceeds from Paycheck Protection Program Loan     323        
Repayment of Paycheck Protection Program Loan     (323 )      
Net cash provided by financing activities     6,727       163  
Effect of foreign exchange rate changes on cash     21       (7 )
Net decrease in cash     (2,779 )     (16,564 )
Cash at beginning of period     5,459       25,583  
Cash at end of period   $ 2,680     $ 9,019  

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
[email protected]

Lantronix Reports First Quarter Fiscal 2021 Results

  • First
    Quarter Net Revenue
    W
    as
    $
    17.
    1
    Million, Up
    35
    %
    F
    rom
    the
    Prior Year
    ,
    Down
    1
    % Sequentially
  • GAAP Gross Margin Improved
    1,040
    Basis Points to
    48.1
    % Sequentially
  • GAAP EPS
    Improved to
    ($0.
    0
    1
    )
    p
    er
    S
    hare
  • Non-GAAP EPS
    W
    as
    $0.
    0
    5
    per share
    , Driven by
    Gross Margin Strength
    ,
    Integration
    ,
    and
    Expense Controls
  • Company
    Reiterates
    Fiscal 2021
    Revenue Growth
    Target
    of 20%
    -25%
    and
    Non-GAAP EPS Growth
    of
    120

    160
    %

IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Lantronix, Inc. (NASDAQ: LTRX), a global provider of software as a service (“SaaS”), engineering services, and intelligent hardware for the Internet of Things (IoT) and Remote Environment Management (REM), today reported results for the first quarter of fiscal 2021 that ended September 30, 2020.

Net revenue totaled $17.1 million, up 35 percent year over year and down 1 percent sequentially.

GAAP EPS improved to ($0.01), compared to ($0.06) in the prior fiscal quarter.

Non-GAAP EPS was $0.05, compared to $0.04 in the prior fiscal quarter.

“Profitability improved nicely in the first quarter, driven by gross margin strength, ongoing integrations and rigorous expense controls,” stated Paul Pickle, president and CEO of Lantronix. “While supply chain disruptions related to COVID-19 continue to impact our ability to meet customer demand, opportunities are on the rise and we remain confident in our 2021 revenue and earnings forecasts.”

Business Outlook

Due to the ongoing uncertainties caused by the COVID-19 pandemic that continue to impact supply chains, Lantronix has transitioned from specific quarterly guidance in favor of annual growth targets.   For the full year fiscal 2021, the company continues to expect year over year revenue growth of 20-25 percent, with non-GAAP EPS growth on the order of 120-160 percent.

Conference Call and Webcast

Lantronix will host an investor conference call and audio webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its results for the first quarter of fiscal 2021 that ended Sept. 30, 2020. To access the live conference call, investors should dial 1-844-802-2442 (US) or 1-412-317-5135 (international) and indicate that they are participating in the Lantronix Q1 FY 2021 call. The webcast will be available simultaneously via the investor relations section of the Company’s website at www.lantronix.com.

Investors can access a replay of the conference call starting at approximately 5:00 p.m. Pacific Time today at www.lantronix.com. A telephonic replay will also be available through Nov. 19, 2020, by dialing 1-877-344-7529 (US) or 1-412-317-0088 (international) and entering passcode 10149339.

About Lantronix

Lantronix, Inc. is a global provider of software as a service (“SaaS”), engineering services, and hardware for Edge Computing, the Internet of Things (IoT), and Remote Environment Management (REM). Lantronix enables its customers to provide reliable and secure solutions while accelerating their time to market. Lantronix’s products and services dramatically simplify operations through the creation, development, deployment, and management of customer projects at scale while providing quality, reliability and security.

Lantronix’s portfolio of services and products address each layer of the IoT Stack including Collect, Connect, Compute, Control and Comprehend, enabling its customers to deploy successful IoT and REM solutions. Lantronix’s services and products deliver a holistic approach, addressing its customers’ needs by integrating a SaaS management platform with custom application development layered on top of external and embedded hardware enabling intelligent edge computing, secure communications (wired, Wi-Fi, and cellular), location and positional tracking, and environmental sensing and reporting.

With three decades of proven experience in creating robust industry and customer specific solutions, Lantronix is an innovator in enabling its customers to build new business models, leverage greater efficiencies and realize the possibilities of the Internet of Things and Remote Environment Management. Lantronix’s solutions are deployed inside millions of machines at data centers, offices, and remote sites serving a wide range of industries, including energy, agriculture, medical, security, manufacturing, distribution, transportation, retail, financial, environmental, infrastructure and government.

For more information, visit www.lantronix.com.

Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix

References in this Report to “fiscal 2021” refer to the fiscal year ended June 30, 2021 and references to “fiscal 2020” refer to the fiscal year ended June 30, 2020.

Discussion of Non-GAAP Financial Measures

Lantronix believes that the presentation of non-GAAP financial information, when presented in conjunction with the corresponding GAAP measures, provides important supplemental information to management and investors regarding financial and business trends relating to the company’s financial condition and results of operations. Management uses the aforementioned non-GAAP measures to monitor and evaluate ongoing operating results and trends to gain an understanding of our comparative operating performance. The non-GAAP financial measures disclosed by the company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations of the non-GAAP financial measures to the financial measures calculated in accordance with GAAP should be carefully evaluated. The non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Non-GAAP net income (loss) consists of net income (loss) excluding (i) share-based compensation and the employer portion of withholding taxes on stock grants, (ii) depreciation and amortization, (iii) interest income (expense), (iv) other income (expense), (v) income tax provision (benefit), (vi) severance and restructuring charges, (vii) acquisition related costs, (viii) impairment of long-lived assets, (ix) amortization of purchased intangibles, and (x) amortization of manufacturing profit in acquired inventory.

Non-GAAP net income (loss) per share is calculated by dividing non-GAAP net income (loss) by non-GAAP weighted-average shares outstanding (diluted). For purposes of calculating non-GAAP net income (loss) per share, the calculation of GAAP weighted-average shares outstanding (diluted) is adjusted to exclude share-based compensation, which for GAAP purposes is treated as proceeds assumed to be used to repurchase shares under the GAAP treasury stock method.

Guidance on earnings per share growth is provided only on a non-GAAP basis due to the inherent difficulty of forecasting the timing or amount of certain items that have been excluded from the forward-looking non-GAAP measures, and a reconciliation to the comparable GAAP guidance has not been provided because certain factors that are materially significant to Lantronix’s ability to estimate the excluded items are not accessible or estimable on a forward-looking basis without unreasonable effort.

Forward-Looking Statements

This news release contains forward-looking statements, including statements concerning our projected operating and financial performance
for
fiscal 2021, the short- and long-term impact of COVID-19 on our business,
our ability to innovate
and
to enable new business models, leverage greater efficiencies and realize the possibilities of the Internet of Things and Remote Environment Management as well as the benefits that might be derived from the efforts of our team to transform our business. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our results or experiences, or future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: the impact of COVID-19 and the measures to reduce its spread on our employees, supply and distribution chains, the global economy and our financial condition and liquidity; the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to continue to generate revenue from products sold into mature markets; our ability to develop, market, and sell new products; our ability to succeed with our new software offerings; fluctuations in our revenue due to the project-based timing of orders from certain customers; unpredictable timing of our revenues due to the lengthy sales cycle for our products and services and potential delays in customer completion of projects; our ability to accurately forecast future demand for our products; delays in qualifying revisions of existing products; constraints or delays in the supply of, or quality control issues with, certain materials or components; difficulties associated with the delivery, quality or cost of our products from our contract manufacturers or suppliers; risks related to the outsourcing of manufacturing and international operations; difficulties associated with our distributors or resellers; intense competition in our industry and resultant downward price pressure; rises in inventory levels and inventory obsolescence; undetected software or hardware errors or defects in our products; cybersecurity risks; our ability to obtain appropriate industry certifications or approvals from governmental regulatory bodies; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; uncertainty as to the future profitability of acquired businesses, and delays in the realization of, or the failure to realize, any accretion from acquisition transactions; acquiring, managing and integrating new operations, businesses or assets, and the associated diversion of management attention or other related costs or difficulties; our ability to protect patents and other proprietary rights and avoid infringement of others’ proprietary technology rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; our ability to attract and retain qualified management; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, and in our other public filings with the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections

Lantronix Investor Relations Contact:        
Jeremy Whitaker
Chief Financial Officer
[email protected]

© 2020 Lantronix, Inc. All rights reserved. Lantronix and XPort are registered trademarks, and ConsoleFlow is a trademark, of Lantronix, Inc.

LANTRONIX, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
 (In thousands)
         
    September 30


  June 30,
    2020   2020
Assets        
Current assets:        
Cash and cash equivalents   $ 7,709     $ 7,691  
Accounts receivable, net     12,345       11,411  
Inventories, net     13,888       13,781  
Contract manufacturers’ receivable     551       337  
Prepaid expenses and other current assets     1,690       1,290  
Total current assets     36,183       34,510  
Property and equipment, net     1,555       1,587  
Goodwill     15,810       15,810  
Purchased intangible assets, net     11,567       12,449  
Lease right-of-use assets     2,974       3,345  
Other assets     241       232  
Total assets   $ 68,330     $ 67,933  
         
Liabilities and stockholders’ equity        
Current liabilities:        
Accounts payable   $ 6,676     $ 5,331  
Accrued payroll and related expenses     2,390       2,658  
Short-term debt, net     1,472       1,472  
Other current liabilities     6,339       6,308  
Total current liabilities     16,877       15,769  
Long-term debt, net     3,314       3,682  
Other non-current liabilities     1,640       1,962  
Total liabilities     21,831       21,413  
         
Commitments and contingencies        
         
Stockholders’ equity:        
Common stock     3       3  
Additional paid-in capital     246,546       246,265  
Accumulated deficit     (200,421 )     (200,119 )
Accumulated other comprehensive income   371       371  
Total stockholders’ equity     46,499       46,520  
Total liabilities and stockholders’ equity   $ 68,330     $ 67,933  
         
LANTRONIX, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
               
               
    Three Months Ended  
    September 30,   June 30,   September 30,  
    2020   2020   2019  
Net revenue   $ 17,146     $ 17,397     $ 12,741    
Cost of revenue     8,907       10,846       6,546    
Gross profit     8,239       6,551       6,195    
Operating expenses:              
Selling, general and administrative     4,899       4,680       4,473    
Research and development     2,572       2,010       2,621    
Restructuring, severance and related charges     92       478       749    
Acquisition-related costs           38       643    
Amortization of purchased intangible assets     882       941       144    
Total operating expenses     8,445       8,147       8,630    
Loss from operations     (206 )     (1,596 )     (2,435 )  
Interest income (expense), net     (85 )     (90 )     56    
Other income (expense), net     39       1       (43 )  
Loss before income taxes     (252 )     (1,685 )     (2,422 )  
Provision for income taxes     50       16       48    
Net loss   $ (302 )   $ (1,701 )   $ (2,470 )  
Net loss per share – basic and diluted   $ (0.01 )   $ (0.06 )   $ (0.11 )  
Weighted-average common shares – basic and diluted     28,371       28,046       22,913    
               
LANTRONIX, INC.
UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTMENTS
(In thousands, except per share data)
               
    Three Months Ended  
    September 30,   June 30,   September 30,  
    2020   2020
  2019  
GAAP net loss   $ (302 )   $ (1,701 )   $ (2,470 )  
Non-GAAP adjustments:              
Cost of revenue:              
Share-based compensation     58       85       24    
Employer portion of withholding taxes on stock grants                 1    
Depreciation and amortization     177       179       67    
Total adjustments to cost of revenue     235       264       92    
Selling, general and administrative:              
Share-based compensation     445       783       459    
Employer portion of withholding taxes on stock grants     5       12       5    
Depreciation and amortization     55       69       54    
Total adjustments to selling, general and administrative     505       864       518    
Research and development:              
Share-based compensation     100       122       95    
Employer portion of withholding taxes on stock grants     6       2       4    
Depreciation and amortization     33       27       26    
Total adjustments to research and development     139       151       125    
Restructuring, severance and related charges     92       478       749    
Acquisition related costs           38       643    
Amortization of purchased intangible assets     882       941       144    
Amortization of manufacturing profit in acquired inventory   7       51       171    
Total non-GAAP adjustments to operating expenses     1,625       2,523       2,350    
Interest (income) expense, net     85       90       (56 )  
Other (income) expense, net     (39 )     (1 )     43    
Provision for income taxes     50       16       48    
Total non-GAAP adjustments     1,956       2,892       2,477    
Non-GAAP net income   $ 1,654     $ 1,191     $ 7    
               
               
Non-GAAP net income per share – diluted   $ 0.05     $ 0.04     $ 0.00    
               
Denominator for GAAP net income per share – basic     28,371       28,046       22,913    
Non-GAAP adjustment     1,833       1,959       1,834    
Denominator for non-GAAP net income per share – diluted     30,204       30,005       24,747    
               
GAAP operating expenses   $ 8,445     $ 8,147     $ 8,630    
Non-GAAP adjustments to operating expenses     (1,625 )     (2,523 )     (2,350 )  
Non-GAAP operating expenses   $ 6,820     $ 5,624     $ 6,280    
               

LANTRONIX, INC.
UNAUDITED NET REVENUES BY PRODUCT LINE AND REGION
(In thousands)
             
  Three Months Ended  
  September 30, 2020   June 30, 2020   September 30, 2019  
IoT $ 14,620   $ 14,588   $ 10,221  
REM   2,402     2,671     2,301  
Other   124     138     219  
  $ 17,146   $ 17,397   $ 12,741  
             
             
  Three Months Ended  
  September 30, 2020   June 30, 2020   September 30, 2019  
Americas $ 10,929   $ 11,549   $ 5,764  
EMEA   2,639     3,093     4,521  
Asia Pacific Japan   3,578     2,755     2,456  
  $ 17,146   $ 17,397   $ 12,741  
             

 

INTRUSION Reports Third Quarter 2020 Results

Positive Response to Beta Testing of New Cybersecurity Solution
and

Strengthened Balance Sheet with Successful Follow-On Offering

PLANO, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) — INTRUSION, Inc. (NASDAQ: INTZ) announced today financial results for the three- and nine-month periods ended September 30, 2020.

Third Quarter and Recent Business Highlights

  • With positive beta-testing results, accepts pre-orders for INTRUSION Shield
  • $18.1 million in net proceeds raised from a public offering of common shares
  • Successfully uplisted to the Nasdaq Capital Market
  • Expansion of executive team with key appointments to support growth strategy

“While extended government shutdowns associated with the pandemic continued to impact our legacy subscription and reporting businesses during the third quarter, the growing trend of sophisticated cybersecurity attacks underscores the crucial need for more advanced, innovative solutions,” stated Jack B. Blount, President and CEO of INTRUSION. “We are capitalizing on this need through the recent introduction and aggressive ramp of our new Shield family of disruptive cybersecurity solutions.

Recent feedback from enterprise customers that are beta testing Shield has been extraordinarily positive, which is why we made the decision to take pre-orders ahead of general availability. Leveraging our unique proprietary database of threat indicators and advanced AI, Shield detects and neutralizes threats that are actively inside customers’ networks, effectively tackling the problem of vulnerability from the inside out. Shield will disrupt the cybersecurity industry beginning with the enterprise market, which represents more than a $7 billion opportunity in the U.S. alone. Moreover, the launch of subsequent solutions within the Shield family will also increase our addressable market, further fueling our growth.”

Third Quarter Financial Results

Revenue for the third quarter 2020 was $1.6 million, compared to $3.9 million in the third quarter 2019 and $1.7 million for the second quarter 2020.

Gross profit margin was 59 percent of revenue in the third quarter of 2020, compared to 62 percent in the third quarter 2019 and 61 percent in the second quarter 2020.

INTRUSION’s third quarter 2020 operating expenses were $2.3 million, compared to $0.9 million in the third quarter 2019 and $1.7 million in the second quarter 2020.

INTRUSION’s net loss was $1.4 million in the third quarter 2020, compared to net income of $1.5 million in the third quarter 2019 and a net loss of $0.7 million in the second quarter 2020.

As of September 30, 2020, INTRUSION reported cash, cash equivalents and accounts receivables of $2.5 million. Subsequent to quarter end, INTRUSION raised $18.1 million in net proceeds from a follow-on offering of 3.6 million shares of its common stock. The net proceeds reflect 2.5 million shares offered by the Company, including the underwriter’s exercised option to purchase an additional 465,000 shares.

Conference Call

Intrusion’s management will host a conference call today at 4:00 P.M. CST. Interested investors can access the call at 1-833-366-0416 or +1-236-712-2506 for international callers and provide the following Conference ID: 5795593. For those unable to participate in the live conference call, a replay will be accessible beginning tonight at 7:00 P.M. CST until November 19, 2020 by calling 1-800-585-8367 or +1-416-621-4642 for international callers. At the replay prompt, enter conference identification number 5795593. Additionally, a live and archived audio webcast of the conference call will be available at www.intrusion.com.

About INTRUSION Inc.

I
NTRUSION Inc. is a global provider of entity identification, high speed data mining, cybercrime and advanced persistent threat detection products. INTRUSION’s solution families include Shield™, a combination of plug-n-play hardware, software, global data, and real-time Artificial Intelligence (AI) services that provide organizations with the most robust cybersecurity defense possible, TraceCop for identity discovery and disclosure, and Savant™ for network data mining and advanced persistent threat detection. INTRUSION’s solutions help protect critical information assets by quickly detecting, protecting, analyzing and reporting attacks or misuse of classified, private and regulated information for government and enterprise networks. For more information, please visit www.intrusion.com.

This release may contain certain forward-looking statements, which reflect management’s expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties.
Such statements include, without limitations, statements regarding future revenue growth and profitability, the difficulties in forecasting future sales caused by current economic and market conditions, the effects of sales and implementation cycles for our products on our quarterly results and difficulties in accurately estimating market growth, uncertainties regarding future government and corporate spending on information security products, spending patterns of, and appropriations to, U.S. government departments, statements about our new INTRUSION Shield solution and its success and future market acceptance, as well as other statements. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements. The factors that could cause actual results to differ materially from expectations are detailed in the Company’s most recent reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.”

Company Contact

Julia Kramer, VP Marketing
[email protected]
P: 972-301-3635

Investor Relations Contact

Joel Achramowicz
[email protected]
P: (415) 845-9964

 





INTRUSION INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands except par value amounts)

  September 30,     December 31,
  2020     2019
ASSETS        
Current Assets            
Cash and cash equivalents $ 1,505     $ 3,334  
Accounts receivable 1,030       1,556  
Prepaid expenses 647       152  
Total
current
assets
3,182       5052  
Noncurrent Assets        
Property and equipment, net 356       335  
Finance leases right-of-use asset, net 30       62  
Operating leases right-of-use asset, net 1,160       1,348  
Other assets 57       38  
Total noncurrent assets 1,603       1,783  
TOTAL ASSETS $ 4,785     $ 6,835  

LIABILITIES AND EQUITY (DEFICIT)

Current Liabilities      
Accounts payable and accrued expenses $ 1,420     $ 1,080  
Dividends payable     20  
Finance leases liability, current portion 31     43  
Operating leases liability, current portion 295     284  
PPP loan payable, current portion 392      
Deferred revenue 58     516  
Total current liabilities 2,196     1,943  
Finance leases liability, noncurrent portion 1     21  
PPP loan payable, noncurrent portion 239      
Operating lease liability, noncurrent portion 1,095     1,315  
Total noncurrent liabilities 1,335     1,336  
Stockholders’ Equity:      
Preferred stock, $.01 par value:      
Authorized shares – 5,000      
Series 1 shares issued and outstanding – 200 in 2019      
Liquidation preference of $1,013 in 2019     707  
Series 2 shares issued and outstanding – 460 in 2019
Liquidation preference of $1,155 in 2019
    724  
Series 3 shares issued and outstanding – 289 in 2019
Liquidation preference of $634 in 2019
    412  
Common stock, $.01 par value:      
Authorized shares – 80,000      
Issued shares – 14,939 in 2020 and 13,552 in 2019
Outstanding shares – 14,929 in 2020 and 13,542 in 2019
149     136  
Common stock held in treasury, at cost – 10 shares (362 )   (362 )
Additional paid-in capital 58,877     56,759  
Accumulated deficit (57,367 )   (54,777 )
Accumulated other comprehensive loss (43 )   (43 )
Total stockholders’ equity 1,254     3,556  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 4,785     $ 6,835  
               





INTRUSION INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands except per share amounts)

    Three
Months Ended

September
30,
  N
i
ne
Months Ended

September 30,
 
    20
20
  201
9
  20
20
  201
9
 
Revenue   $ 1,588   $ 3,860   $ 5,039   $ 11,071  
Cost of revenue   652   1,465   2,050   4,339  
                   
Gross profit   936   2,395   2,989   6,732  
                   
Operating expenses:                  
Sales and marketing   885   356   1,880   813  
Research and development   1,081   297   2,741   775  
General and administrative   377   277   962   930  
                   
Operating income (loss)   (1,407 ) 1,465   (2,594 ) 4,214  
Interest expense   (2 ) (1 ) (4 ) (45 )
Interest income       8    
                   
Net income (loss)   $ (1,409 ) $ 1,464   $ (2,590 ) $ 4,169  
                   
Preferred stock dividends accrued   (13 ) (35 ) (79 ) (104 )
Net income (loss) attributable to common stockholders   $ (1,422 ) $ 1,429   $ (2,669 ) $ 4,065  
                   
Net income (loss) per share attributable to common stockholders:                  
Basic   $ (0.10 ) $ 0.11   $ (0.19 ) $ 0.30  
Diluted   $ (0.10 ) $ 0.09   $ (0.19 ) $ 0.27  
                   
Weighted average common shares outstanding:                  
Basic   14,450   13,523   13,981   13,466  
Diluted   14,450   15,371   13,981   15,314  

 

Dynagas LNG Partners LP Reports Results for the Three and Nine Months Ended September 30, 2020

ATHENS, Greece, Nov. 12, 2020 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: “DLNG”) (“Dynagas Partners” or the “Partnership”), an owner and operator of liquefied natural gas (“LNG”) carriers, today announced its results for the three and nine months ended September 30, 2020.

Third Quarter Highlights:

  • Net income and earnings per common unit of $10.0 million and $0.20, respectively;
  • Adjusted Net Income(1) of $10.2 million and Adjusted Earnings per common unit of $0.21;
  • Adjusted EBITDA(1) of $24.2 million;
  • 100% fleet utilization;
  • Declared and paid cash distribution of $0.5625 per unit on its Series A Preferred Units (NYSE: “DLNG PR A”) for the period from May 12, 2020 to August 11, 2020 and $0.546875 per unit on the Series B Preferred Units (NYSE: “DLNG PR B”) for the period from May 22, 2020 to August 21, 2020; and
  • Entered into an amended and restated ATM Sales Agreement (the “A&R Sales Agreement”), for the offer and sale of common units representing limited partnership interests, having an aggregate offering price of up to $30.0 million (the “Current ATM Program”). Upon entry into the A&R Sales Agreement, the Partnership terminated its prior at-the-market program established in July of 2020 (the “Prior ATM Program”). At the time of such termination, $0.4 million of the Partnership’s common units out of an aggregate of $30.0 million of its common units were sold pursuant to the Prior ATM Program.

Subsequent Events:

  • Declared a quarterly cash distribution of $0.5625 on the Partnership’s Series A Preferred Units for the period from August 12, 2020 to November 11, 2020, which was paid on November 12, 2020; and
  • Declared a quarterly cash distribution of $0.546875 on the Partnership’s Series B Preferred Units for the period from August 22, 2020 to November 21, 2020, which is payable on November 23, 2020.

 (1) Adjusted Net Income, Adjusted Earnings per common unit, and Adjusted EBITDA are not recognized measures under U.S. GAAP. Please refer to Appendix B of this press release for the definitions and reconciliation of these measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP and other related information.

CEO Commentary:

We are pleased to report the results for the three months and nine months ended September 30, 2020. All six LNG carriers in our fleet are operating under their respective long-term charters with international gas producers with an average remaining contract term of 7.9 years. Our estimated contracted revenue backlog is approximately $1.15 billion. Absent any unforeseen events or unscheduled dry dockings, our fleet is contracted to be employed 100% for 2020, 92% for 2021 and 83% for 2022 through and including 2025. The earliest contracted re-delivery date for our six LNG carriers is in the third quarter of 2021(the Arctic Aurora), with the next carrier (the Clean Energy) becoming available for re-chartering in the first quarter of 2026 at the earliest.

For the third quarter of 2020, we reported Net Income of $10.0 million and Adjusted EBITDA of $24.2 million. This improved performance is attributable to an increase in voyage revenues and a decrease in interest and finance costs compared to the corresponding period in 2019, coupled with stable vessel operating expenses during this period.

Despite the ongoing operational challenges the industry is facing as a result of the COVID-19 outbreak, we are pleased to report 100% utilization for our fleet for the third quarter of 2020. The ongoing impact of the COVID-19 outbreak has been operationally manageable due to our manager’s COVID-19 response plan which has been implemented with the support of our seafarers, charterers and employees, for which we are grateful.

Going forward, we intend to continue our strategy of using our cash flow generation to deleverage our balance sheet and reinforce our liquidity so as to build equity value over time. This, we believe, will enhance our ability to pursue future growth initiatives.

Financial Results Overview:


 
Three Months Ended   Nine Months Ended

(U.S. dollars in thousands, except per unit data)
  September 30,
2020
(unaudited)
    September 30,
2019
(unaudited)
    September 30,
2020
(unaudited)
    September 30,
2019
(unaudited)
Voyage revenues $ 34,346   $ 34,364     $ 102,730   $ 96,584  
Net Income / (Loss) $ 10,015   $ (4,740 )   $ 23,409   $ (1,916 )
Adjusted Net Income (1) $ 10,203   $ 2,775     $ 27,161   $ 5,277  
Operating income $ 16,149   $ 16,061     $ 48,018   $ 43,963  
Adjusted EBITDA(1) $ 24,221   $ 23,775     $ 72,091   $ 66,366  
Earnings/ (Loss) per common unit $ 0.20   $ (0.21 )   $ 0.41   $ (0.30 )
Adjusted Earnings/ (Loss) per common unit (1) $ 0.21   $     $ 0.52   $ (0.10 )
                       

(1) Adjusted Net Income, Adjusted EBITDA, and Adjusted Earnings/(Loss) per common unit are not recognized measures under U.S. GAAP. Please refer to Appendix B of this press release for the definitions and reconciliation of these measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

Three Months Ended September 30, 2020 and 2019 Financial Results

Net Income for the three months ended September 30, 2020 was $10.0 million as compared to a Net Loss of $4.7 million in the corresponding period of 2019, which represents an increase of $14.7 million, or 312.8%. This increase was mainly attributable to a decrease in interest and finance costs in the three months ended September 30, 2020, as further analyzed below.

Adjusted Net Income for the three months ended September 30, 2020 was $10.2 million compared to $2.8 million in the corresponding period of 2019, representing a net increase of $7.4 million or 264.3%.

Voyage revenues for the three-month periods ended September 30, 2020 and 2019 were $34.3 million and $34.4 million, respectively.

The Partnership reported average daily hire gross of commissions(1) of approximately $62,500 per day per vessel in the three-month period ended September 30, 2020, compared to approximately $62,200 per day per vessel in the corresponding period of 2019. During the three-month periods ended September 30, 2020 and September 30, 2019, the Partnership’s vessels operated at 100% and 99% utilization, respectively.

Vessel operating expenses were $7.2 million, which corresponds to a daily rate per vessel of $13,074 in the three-month period ended September 30, 2020, as compared to $7.5 million, or a daily rate per vessel of $13,531 in the corresponding period of 2019.

Adjusted EBITDA for the three months ended September 30, 2020 was $24.2 million, as compared to $23.8 million for the corresponding period of 2019, which corresponds to an increase of $0.4 million, or 1.7%.

Interest and finance costs, net, were $6.0 million in the three months ended September 30, 2020 as compared to $20.9 million in the corresponding period of 2019, which represents a decrease of $14.9 million, or 71.3%. The decrease in interest and finance costs is due to (i) the lower weighted average interest rate, (ii) the reduction in the average interest bearing debt and (iii) the decrease in deferred loan fees as a result of a $7.5 million one-time write-off of deferred loan fees included in the corresponding period of 2019 in connection with the early prepayment of the $480 million Senior Secured Term Loan facility in September 2019.

For the three months ended September 30, 2020, the Partnership reported Earnings per common unit and Adjusted Earnings per common unit, basic and diluted, of $0.20 and $0.21 respectively, after taking into account the distributions relating to the Series A Preferred Units and the Series B Preferred Units on the Partnership’s Net income/Adjusted Net Income. Earnings per common unit and Adjusted Earnings per common unit, basic and diluted, are calculated on the basis of a weighted average number of 35,593,477 common units outstanding during the period and in the case of Adjusted Earnings per common unit after reflecting the impact of the non-cash items presented in Appendix B of this press release.

Adjusted Net Income, Adjusted EBITDA and Adjusted Earnings/(Loss) per common unit are not recognized measures under U.S. GAAP. Please refer to Appendix B of this press release for the definitions and reconciliation of these measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

Amounts relating to variations in period–on–period comparisons shown in this section are derived from the condensed financials presented below.

(1) Average daily hire gross of commissions represents voyage revenue excluding the non-cash time charter deferred revenue amortization, divided by the Available Days in the Partnership’s fleet as described in Appendix B.

Liquidity/ Financing/ Cash Flow Coverage

During the three months ended September 30, 2020, the Partnership generated net cash from operating activities of $27.6 million as compared to $13.6 million in the corresponding period of 2019, which represents an increase of $14.0 million, or 102.9%.

As of September 30, 2020, the Partnership reported total cash of $76.0 million (including $50.0 million of restricted cash). The Partnership’s outstanding indebtedness as of September 30, 2020 under the $675.0 Million Credit Facility amounted to $627.0 million, gross of unamortized deferred loan fees and including $48.0 million, which is repayable within one year.

In July 2020, the Partnership, under the Prior ATM program, issued and sold 122,580 common units at a weighted average price of $3.665 per unit, resulting in gross proceeds of $0.4 million and net proceeds of $0.3 million. No issuances of common units under the Current ATM program were made during the three months ended September 30, 2020.

As of September 30, 2020, the Partnership had unused availability of $30.0 million under its interest free $30.0 million revolving credit facility with its Sponsor, or the $30.0 Million Revolving Credit Facility, which was extended on November 14, 2018, and is available to the Partnership at any time until November 2023.

Vessel Employment

As of November 12, 2020, the Partnership had estimated contracted time charter coverage(1) for 100% of its fleet estimated Available Days (as defined in Appendix B) for 2020, 92% of its fleet estimated Available Days for 2021 and 83% of its fleet estimated Available Days for 2022.

As of the same date, the Partnership’s contracted revenue backlog estimate (2) (3) was $1.15 billion, with an average remaining contract term of 7.9 years.                      

(1) Time charter coverage for the Partnership’s fleet is calculated by dividing the fleet contracted days on the basis of the earliest estimated delivery and redelivery dates prescribed in the Partnership’s current time charter contracts, net of scheduled class survey repairs by the number of expected Available Days during that period.

(2) The Partnership calculates its estimated contracted revenue backlog by multiplying the contractual daily hire rate by the expected number of days committed under the contracts (assuming earliest delivery and redelivery and excluding options to extend), assuming full utilization. The actual amount of revenues earned and the actual periods during which revenues are earned may differ from the amounts and periods disclosed due to, for example, dry-docking and/or special survey downtime, maintenance projects, off-hire downtime and other factors that result in lower revenues than the Partnership’s average contract backlog per day.

(3) $0.16 billion of the revenue backlog estimate relates to the estimated portion of the hire contained in certain time charter contracts with Yamal which represents the operating expenses of the respective vessels and is subject to yearly adjustments on the basis of the actual operating costs incurred within each year. The actual amount of revenues earned in respect of such variable hire rate may therefore differ from the amounts included in the revenue backlog estimate due to the yearly variations in the respective vessels’ operating costs.

Conference Call and Webcast:

As announced, the Partnership’s management team will host a conference call on Friday, November 13, 2020 at 10:00 a.m. Eastern Time to discuss the Partnership’s financial results.

Conference Call details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: +1 (877) 553-9962 (US Toll Free Dial In), 0 (808) 238-0669 (UK Toll Free Dial In) or +44 (0) 2071 928592(Standard International Dial In). Please quote “Dynagas.”

A telephonic replay of the conference call will be available until November 19, 2020, by dialing +1(866) 331-1332 (US Toll Free Dial In), 0(808) 238-0667 (UK Toll Free Dial In) or +44 (0) 3333 009785 (Standard International Dial In) and the access code required for the replay is: 59711562#.

Audio Webcast – Slides Presentation:

There will be a live and then archived audio webcast of the conference call, via the internet through the Dynagas LNG Partners website www.dynagaspartners.com. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation on the third quarter ended September 30, 2020 financial results will be available in PDF format 10 minutes prior to the conference call and webcast, accessible on the company’s website www.dynagaspartners.com on the webcast page. Participants to the webcast can download the PDF presentation. None of the information contained in or that forms a part of the Partnership’s conference calls, website or audio webcasts is part of this release.

About Dynagas LNG Partners LP

Dynagas LNG Partners LP. (NYSE: DLNG) is a master limited partnership which owns and operates liquefied natural gas (LNG) carriers employed on multi-year charters. The Partnership’s current fleet consists of six LNG carriers, with aggregate carrying capacity of approximately 914,000 cubic meters.

Visit the Partnership’s website at www.dynagaspartners.com.

Contact Information:

Dynagas LNG Partners LP
Attention: Michael Gregos
Tel. +30 210 8917960
Email: [email protected]  

Investor Relations / Financial Media:

Nicolas Bornozis
Markella Kara
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, NY 10169
Tel. (212) 661-7566
E-mail: [email protected]

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Partnership desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “project”, “will”, “may,” “should,” “expect,” “expected,” “pending” and similar expressions identify forward-looking statements. These forward-looking are not intended to give any assurance as to future results and should not be relied upon.

The forward-looking statements in this press release are based upon various assumptions and estimates, many of which are based, in turn, upon further assumptions, including without limitation, examination by the Partnership’s management of historical operating trends, data contained in its records and other data available from third parties. Although the Partnership believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Partnership’s control, the Partnership cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Partnership’s view, could cause actual results to differ materially from those discussed, expressed or implied, in the forward-looking statements include, but are not limited to, the strength of world economies and currency fluctuations, general market conditions, including fluctuations in charter  rates, ownership days, and  vessel  values,  changes  in  supply and demand  for  Liquefied  Natural  Gas  (LNG)  shipping capacity, changes in the Partnership’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Partnership’s vessels, availability of financing and refinancing, changes in governmental laws, rules and regulations or actions taken by regulatory authorities,  economic, regulatory, political and governmental conditions that affect the shipping and the LNG industry, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns, instances of off-hires, the length and severity of the COVID-19 outbreak, the impact of public health threats and outbreaks of other highly communicable diseases, the impact of the expected discontinuance of LIBOR after 2021 on interest rates of our debt that reference LIBOR, the amount of cash available for distribution, and other factors. Please see the Partnership’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Partnership disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

APPENDIX A

DYNAGAS LNG PARTNERS LP

Condensed Consolidated Statements of Income

(In thousands of U.S. dollars except units and per unit data)   Three Months Ended
September 30,
  Nine Months Ended

September 30,
    2020

(unaudited)
  2019

(unaudited)
  2020

(unaudited)
  2019

(unaudited)
REVENUES                
Voyage revenues $ 34,346   $ 34,364   $ 102,730   $ 96,584  
EXPENSES                
Voyage expenses (including related party)   (695 )   (803 )   (2,305 )   (1,934 )
Vessel operating expenses   (7,217 )   (7,469 )   (21,687 )   (21,286 )
General and administrative expenses (including related party)   (596 )   (737 )   (1,861 )   (1,823 )
Management fees -related party   (1,697 )   (1,648 )   (5,055 )   (4,890 )
Depreciation   (7,992 )   (7,646 )   (23,804 )   (22,688 )
Operating income   16,149     16,061     48,018     43,963  
Interest and finance costs, net   (6,026 )   (20,851 )   (21,126 )   (45,898 )
Loss on derivative instruments   (5 )       (3,357 )    
Other, net   (103 )   50     (126 )   19  
                 
Net income / (Loss) $ 10,015   $ (4,740 ) $ 23,409   $ (1,916 )
Earnings/ (loss) per common unit (basic and diluted)  

$

0.20   $ (0.21 ) $ 0.41   $ (0.30 )
Weighted average number of units outstanding, basic and diluted:                
Common units   35,593,477     35,490,000     35,524,744     35,490,000  



DYNAGAS LNG PARTNERS LP

Consolidated Condensed Balance Sheets

(Expressed in thousands of U.S. Dollars—except for unit data)

    September 30,
2020
(unaudited)
    December 31,
2019
(audited)
ASSETS:          
Cash and cash equivalents and restricted cash (current and non-current) $ 76,046     $ 66,206  
Due from related party (current and non-current)   1,350       1,350  
Other current assets   2,521       1,966  
Vessels, net   892,893       916,697  
Other non-current assets   2,666       2,968  
Total assets $ 975,476     $ 989,187  
           

LIABILITIES
         
Total long-term debt, net of deferred financing costs $ 619,068     $ 653,154  
Total other current liabilities   19,567       16,951  
Derivative financial instrument (current and non-current)   3,181        
Due to related party (current and non-current)   1,747       2,202  
Total other non-current liabilities   3,193       3,173  
Total liabilities $ 646,756     $ 675,480  
           

PARTNERS’ EQUITY
         
General partner  (35,526 units issued and outstanding as at September 30, 2020 and December 31, 2019)   (13 )     (28 )
Common unitholders (35,612,580 units issued and outstanding as at September 30, 2020 and 35,490,000 units issued and outstanding as at December 31, 2019)   202,019       187,021  
Series A Preferred unitholders: (3,000,000 units issued and outstanding as at September 30, 2020 and December 31, 2019)   73,216       73,216  
Series B Preferred unitholders: (2,200,000 units issued and outstanding as at September 30, 2020 and December 31, 2019)   53,498       53,498  
Total partners’ equity $ 328,720     $ 313,707  
           
Total liabilities and partners’ equity $ 975,476     $ 989,187  
               

DYNAGAS LNG PARTNERS LP

Consolidated Statements of Cash Flows

(Expressed in thousands of U.S. Dollars)

                 
                 
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2020     2019     2020     2019  
Cash flows from Operating Activities:                
Net income / (Loss): $ 10,015   $ (4,740 ) $ 23,409   $ (1,916 )
Adjustments to reconcile net income / (loss) to net cash provided by operating activities:                
Depreciation   7,992     7,646     23,804     22,688  
Amortization and write-off of deferred financing fees   626     8,316     1,913     9,927  
Deferred revenue amortization   129     (36 )   233     (430 )
Amortization of deferred charges   54     54     162     126  
Loss on derivative financial instrument   5         3,357      
Changes in operating assets and liabilities:                
Trade accounts receivable   355         (222 )   48  
Prepayments and other assets   196     165     (285 )   (498 )
Inventories   19     1,222     (48 )   421  
Due from/ to related parties   3,275     (749 )   (455 )   (274 )
Deferred charges   108     38     (73 )   (999 )
Trade accounts payable   (54 )   (834 )   (988 )   (449 )
Accrued liabilities   189     128     (122 )   173  
Unearned revenue   4,678     2,350     3,738     888  
                 
Net cash provided by Operating Activities   27,587     13,560     54,423     29,705  
                 
Cash flows from Investing Activities                
Vessel acquisitions and other additions to vessels’ cost                
Net cash used in Investing Activities                
                 
Cash flows from Financing Activities:                
Issuance of common units, net of issuance costs   276         276      
Payment of securities registration and other filing costs   (17 )       (17 )   (139 )
Distributions declared and paid   (2,891 )   (2,890 )   (8,672 )   (13,501 )
Proceeds from long-term debt       675,000         675,000  
Repayment of long-term debt   (12,000 )   (470,400 )   (36,000 )   (472,800 )
Payment of derivative instruments   (170 )       (170 )    
Payment of deferred finance fees       (10,558 )       (10,558 )
Net cash used in Financing Activities   (14,802 )   191,152     (44,583 )   178,002  
                 
Net increase in cash and cash equivalents and restricted cash   12,785     204,712     9,840     207,707  
Cash and cash equivalents and restricted cash at beginning of the period   63,261     112,912     66,206     109,917  
Cash and cash equivalents and restricted cash at end of the period $ 76,046   $ 317,624   $ 76,046   $ 317,624  
                         

APPENDIX B

Fleet statistics

    Three Months Ended
September 30,
  Nine Months Ended
September 30,
(expressed in United states dollars except for operational data)   2020     2019     2020     2019  
Number of vessels at the end of period   6     6     6     6  
Average number of vessels in the period (1)   6     6     6     6  
Calendar Days (2)   552.0     552.0     1,644.0     1,638.0  
Available Days (3)   552.0     552.0     1,644.0     1,638.0  
Revenue earning days (4)   552.0     548.7     1,638.7     1,604.3  
Time Charter Equivalent (5) $ 60,962   $ 60,799   $ 61,086   $ 57,784  
Fleet Utilization (4)   100 %   99 %   99.7 %   98 %
Vessel daily operating expenses (6) $ 13,074   $ 13,531   $ 13,192   $ 12,995  

(1) Represents the number of vessels that constituted the Partnership’s fleet for the relevant period, as measured by the sum of the number of days that each vessel was a part of the Partnership’s fleet during the period divided by the number of Calendar Days (defined below) in the period.
(2) “Calendar Days” are the total days that the Partnership possessed the vessels in its fleet for the relevant period.
(3) “Available Days” are the total number of Calendar Days that the Partnership’s vessels were in its possession during a period, less the total number of scheduled off-hire days during the period associated with major repairs, or dry-dockings.
(4) The Partnership calculates fleet utilization by dividing the number of its Revenue earning days, which are the total number of Available Days of the Partnership’s vessels net of unscheduled off-hire days (which do not include positioning/ repositioning days for which compensation has been received) during a period by the number of Available Days. The shipping industry uses fleet utilization to measure a company’s efficiency in finding employment for its vessels and minimizing the amount of days that its vessels are off-hire for reasons such as unscheduled repairs but excluding scheduled off-hires for vessel upgrades, dry-dockings or special or intermediate surveys.
(5) Time charter equivalent rate (“TCE rate”), is a measure of the average daily revenue performance of a vessel. For time charters, this is calculated by dividing total voyage revenues, less any voyage expenses, by the number of Available Days during that period. Under a time charter, the charterer pays substantially all vessel voyage related expenses. However, the Partnership may incur voyage related expenses when positioning or repositioning vessels before or after the period of a time charter, during periods of commercial waiting time or while off-hire during dry-docking or due to other unforeseen circumstances. The TCE rate is not a measure of financial performance under U.S. GAAP (non-GAAP measure), and should not be considered as an alternative to voyage revenues, the most directly comparable GAAP measure, or any other measure of financial performance presented in accordance with U.S. GAAP. However, the TCE rate is a standard shipping industry performance measure used primarily to compare period-to-period changes in a company’s performance and to assist the Partnership’s management in making decisions regarding the deployment and use of the Partnership’s vessels and in evaluating their financial performance. The Partnership’s calculation of TCE rates may not be comparable to that reported by other companies. The following table reflects the calculation of the Partnership’s TCE rates for the three and nine months ended September 30, 2020 and 2019 (amounts in thousands of U.S. dollars, except for TCE rates, which are expressed in U.S. dollars, and Available Days):
   

    Three Months Ended

September 30,
  Nine Months Ended
September 30,
    2020     2019     2020     2019  
(In thousands of U.S. dollars, except for Available Days and TCE rate)                
Voyage revenues $ 34,346   $ 34,364   $ 102,730   $ 96,584  
Voyage Expenses *   (695 )   (803 )   (2,305 )   (1,934 )
Time Charter equivalent revenues $ 33,651   $ 33,561   $ 100,425   $ 94,650  
Available Days   552.0     552.0     1,644.0     1,638.0  
Time charter equivalent (TCE) rate $ 60,962   $ 60,799   $ 61,086   $ 57,784  

*Voyage expenses include commissions of 1.25% paid to Dynagas Ltd., the Partnership’s Manager, and third party ship brokers, when defined in the charter parties, bunkers, port expenses and other minor voyage expenses.

 (6) Daily vessel operating expenses, which include crew costs, provisions, deck and engine stores, lubricating oil, insurance, spares and repairs and flag taxes, are calculated by dividing vessel operating expenses by fleet Calendar Days for the relevant time period.
   

Reconciliation of U.S. GAAP Financial Information to Non-GAAP Financial Information

Reconciliation of Net Income to Adjusted EBITDA

    Three Months Ended
September 30,
  Nine Months Ended
September 30,
(In thousands of U.S.  dollars)   2020     2019       2020     2019  
Net income / (Loss) $ 10,015   $ (4,740 )   $ 23,409   $ (1,916 )
Net interest and finance costs (1)   6,026     20,851       21,126     45,898  
Depreciation   7,992     7,646       23,804     22,688  
Loss on derivative financial instrument   5           3,357      
Amortization of deferred revenue   129     (36 )     233     (430 )
Amortization of deferred charges   54     54       162     126  
Adjusted EBITDA $ 24,221   $ 23,775     $ 72,091   $ 66,366  


(1)

Includes interest and finance costs and interest income, if any.

The Partnership defines Adjusted EBITDA as earnings before interest and finance costs, net of interest income (if any), gains/losses on derivative financial instruments, taxes (when incurred), depreciation and amortization (when incurred), class survey costs and significant non-recurring items (if any). Adjusted EBITDA is used as a supplemental financial measure by management and external users of financial statements, such as investors, to assess the Partnership’s operating performance.

The Partnership believes that Adjusted EBITDA assists its management and investors by providing useful information that increases the ability to compare the Partnership’s operating performance from period to period and against that of other companies in its industry that provide Adjusted EBITDA information. This increased comparability is achieved by excluding the potentially disparate effects between periods or against companies of interest, other financial items, depreciation and amortization and taxes, which items are affected by various and possible changes in financing methods, capital structure and historical cost basis and which items may significantly affect net income between periods. The Partnership believes that including Adjusted EBITDA as a measure of operating performance benefits investors in (a) selecting between investing in the Partnership and other investment alternatives and (b) monitoring the Partnership’s ongoing financial and operational strength.

Adjusted EBITDA is not intended to and does not purport to represent cash flows for the period, nor is it presented as an alternative to operating income. Further, Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and does not represent and should not be considered as an alternative to net income, operating income, cash flow from operating activities or any other measure of financial performance presented in accordance with U.S. GAAP. Adjusted EBITDA excludes some, but not all, items that affect net income and these measures may vary among other companies. Therefore, Adjusted EBITDA, as presented above, may not be comparable to similarly titled measures of other businesses because they may be defined differently by those other businesses. It should not be considered in isolation or as a substitute for a measure of performance prepared in accordance with GAAP. Any Non-GAAP measures should be viewed as supplemental to, and should not be considered as alternatives to, GAAP measures including, but not limited to net earnings (loss), operating profit (loss), cash flow from operating, investing and financing activities, or any other measure of financial performance or liquidity presented in accordance with GAAP.

Reconciliation of Net Income to Adjusted Net Income available to common unitholders and Adjusted Earnings per common unit

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
(In thousands of U.S.  dollars except for units and per unit data)   2020       2019       2020       2019  
Net Income / (Loss) $ 10,015     $ (4,740 )   $ 23,409     $ (1,916 )
Non-cash expense from accelerated amortization of deferred loan fees         7,497             7,497  
Amortization of deferred revenue   129       (36 )     233       (430 )
Amortization of deferred charges   54       54       162       126  
Loss on derivative financial instrument   5             3,357        
Adjusted Net Income $ 10,203     $ 2,775     $ 27,161     $ 5,277  
Less: Adjusted Net Income attributable to preferred unitholders and general partner   (2,898 )     (2,891 )     (8,690 )     (8,668 )
Common unitholders’ interest in Adjusted Net Income/(Loss) $ 7,305     $ (116 )   $ 18,471     $ (3,391 )
Weighted average number of common units outstanding, basic and diluted:   35,593,477       35,490,000       35,524,744       35,490,000  
Adjusted Earnings/(Loss) per common unit, basic and diluted $ 0.21     $  —     $ 0.52     $ (0.10 )
                               

Adjusted Net Income represents net income before non-recurring expenses (if any), charter hire amortization related to time charters with escalating time charter rates, amortization of fair value of acquired time charters and changes in the fair value of derivative financial instruments. Adjusted Net Income available to common unitholders represents the common unitholders interest in Adjusted Net Income for each period presented. Adjusted Earnings per common unit represents Adjusted Net Income attributable to common unitholders divided by the weighted average common units outstanding during each period presented.

Adjusted Net Income, Adjusted Net Income per common unit and Adjusted Earnings per common unit, basic and diluted, are not recognized measures under U.S. GAAP and should not be regarded as substitutes for net income and earnings per unit, basic and diluted. The    Partnership’s definitions of Adjusted Net Income, Adjusted Net Income per common unit and Adjusted Earnings per common unit, basic and diluted, may not be the same at those reported by other companies in the shipping industry or other industries. The Partnership believes that the presentation of Adjusted Net Income and Adjusted Earnings per unit available to common unitholders are useful to investors because these measures facilitate the comparability and the evaluation of companies in the Partnership’s industry. In addition, the Partnership believes that Adjusted Net Income is useful in evaluating its operating performance compared to that of other companies in the Partnership’s industry because the calculation of Adjusted Net Income generally eliminates the accounting effects of items which may vary for different companies for reasons unrelated to overall operating performance. The Partnership’s presentation of Adjusted Net Income available to common unitholders and Adjusted Earnings per common unit does not imply, and should not be construed as an inference, that its future results will be unaffected by unusual or non-recurring items and should not be considered in isolation or as a substitute for a measure of performance prepared in accordance with GAAP.

Motus GI Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  • Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the Pure-Vu system from early adopter hospitals
  • Q3 Pure-Vu-enabled procedures increased by more than 50% above prior quarterly average
  • First major metropolitan health system collaboration intends to utilize Pure-Vu as new standard for facilitating inpatient colonoscopy.

FORT LAUDERDALE, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.

“In Q3 there was a positive turn in our commercial momentum following the headwinds we faced during the Covid-19 pandemic. I am pleased that we continue to execute our strategy of getting our Pure-Vu system into the hands of nearly two dozen of the most prominent healthcare institutions in the United States. During Q3, we saw these hospitals have ramped up inpatient colonoscopy volumes to approximately 80-90% of pre-pandemic levels. The Motus GI team has remained actively engaged with our early adopter accounts and we are resuming the trajectory we started in Q1, prior to the Covid-19 pandemic. We are seeing positive trends in utilization. Moving forward, we believe we can start to achieve sustainable procedure volumes at target accounts, and we expect to see a continuation of our progress and momentum into the fourth quarter,” stated Tim Moran, Chief Executive Officer of Motus GI.

Progress Updates

Since the first commercial placement of a Pure-Vu® System in October 2019, Motus GI has focused its U.S. sales efforts on early adopter hospitals and larger hospital networks. During this time, Motus GI has placed the Pure-Vu® System in more than 20 of these targeted hospitals. In Q3, the Company initiated new Pure-Vu evaluations at NYU Langone, Ascension – St. John Hospital, and Indiana University, while also resuming activities at several existing sites, including Northwestern Memorial Hospital, who put their new product evaluations on hold while managing the Covid-19 pandemic.

As part of the strategy to drive sustainable and growing Pure-Vu single-use sleeve volumes, the Company will collaborate with major hospitals to develop and implement protocols for inpatient colonoscopies that include the Pure-Vu® System. Last week, the Company announced its first major collaboration with NYU Langone Health on its protocol to include the Pure-Vu System for the effective management of inpatient colonoscopy. The Company believes these protocols can improve patient care and hospital economics. In addition, the Company believes these protocols will likely drive expanded adoption of the Pure-Vu® System among these hospitals over time.

The Company has successfully published several clinical hospital case studies in conjunction with Key Opinion Leaders (KOL) from hospitals currently using the Pure-Vu® System for marketing and training purposes. Motus GI has developed a series of podcasts and KOL webinars to provide broad access to these examples of the impact the Pure-Vu® System can provide as it relates to positive clinical and economic outcomes for treating patients with poorly prepped colons. The podcast series is available at the MotusGI YouTube channel under Pure-Vu Review (Click Here).

In the third quarter of 2020, the Company received notice that the China National Intellectual Property Administration (“CNIPA”) issued a patent covering the method of mounting Motus GI’s proprietary sensing technology and enhanced suction systems with the distal end of a colonoscope. This patent further protects the Company’s flagship product – the Pure-Vu® System – in this key potential market. The Company has now more than 29 granted patents and 27 pending patents protecting the Pure-Vu® System.

Financial Results for the Quarter Ended September 30, 2020

The Company reported revenue of approximately $33,000 for the third quarter of 2020, compared to approximately $3,000 for the same period last year. Revenue for the third quarter is from new account and site reorder sales of Pure-Vu single-use sleeves.

For the three months ended September 30, 2020, the Company reported a net loss of approximately $3.9 million, or a net loss per diluted share of $0.13, compared to $5.2 million, or a net loss per diluted share of $0.18, for the same period last year. During the third quarter, net cash used in operating activities and for the purchase of fixed assets was $2.7 million as compared to $4.8 million for the same period of 2019.  These decreases were primarily attributable to the Company’s cost-cutting measures that were announced on March 30, 2020. These measures reduced the Company’s quarterly cash burn by approximately 50% compared to previously forecasted rates for the second half of 2020.

The Company reported approximately $23.7 million in cash, cash equivalents and investments as of September 30, 2020, compared to $28.7 million as of December 31, 2019. In September 2020, the Company sold common stock and other equity securities which raised net proceeds of approximately $9.2 million.

Conference Call:

The Motus GI management team has scheduled a conference call for today, November 12th, at 4:30 p.m. ET to discuss these results. To access the conference call, investors are invited to dial (877) 407-0792 (U.S. and Canada) or (201) 689-8263 (International). The conference ID number is 13711588. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.motusgi.com or http://public.viavid.com/index.php?id=141815. A replay of the webcast will be archived on the Motus GI website for 90 days following the event.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 30, 2020, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Investor Contact:


Bob Yedid
LifeSci Advisors
(646) 597-6989
[email protected] 

 
Motus GI Holdings, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)
 
    September 30,     December 31,  
    2020     2019  
    (unaudited)     (*)  
             
ASSETS            
             

Current assets
           
Cash and cash equivalents   $ 23,687     $ 20,528  
Investments           8,203  
Accounts receivable     39       65  
Inventory     1,295       1,014  
Prepaid expenses and other current assets     889       339  
Related party receivable     2       18  
Total current assets     25,912       30,167  
                 
Fixed assets, net     994       1,056  
Right-of-use assets     816       1,021  
Other non-current assets     13       13  
    Total assets   $ 27,735     $ 32,257  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY                
                 

Current liabilities
               
Accounts payable and accrued expenses   $ 1,889     $ 2,999  
Operating lease liabilities – current     236       321  
Other current liabilities     413       270  
Term debt, net of debt discount of $23 and $246, respectively     7,977       7,754  
Total current liabilities     10,515       11,344  
                 
Contingent royalty obligation     1,624       1,872  
Operating lease liabilities – non-current     597       713  
Total liabilities     12,736       13,929  
Commitments and contingent liabilities (Note 9)                

Shareholders’ equity
               
Preferred Stock $0.0001 par value; 8,000,000 shares authorized; zero shares issued                
 and outstanding            
Preferred Series A Stock $0.0001 par value; 2,000,000 shares authorized; zero                 
shares issued and outstanding            
Common Stock $0.0001 par value; 115,000,000 shares authorized; 32,182,589 and                
28,811,087 shares issued and outstanding as of September 30, 2020 and
December 31, 2019, respectively
    3       3  
Additional paid-in capital     114,319       102,789  
Accumulated deficit     (99,323 )     (84,464 )
Total shareholders’ equity     14,999       18,328  
Total liabilities and shareholders’ equity   $ 27,735     $ 32,257  
                 
 
 (*)    Derived from audited consolidated financial statements

Motus GI Holdings, Inc. and Subsidiaries 
Condensed Consolidated Statements of Comprehensive Loss
(unaudited, in thousands, except share and per share amounts)
 
   
    Three Months Ended

September 30,
    Nine Months Ended

September 30,
 
    2020     2019     2020     2019  
                         
Revenue   $ 33     $ 3     $ 62     $ 8  
Cost of revenue     32       62       72       65  
Gross profit (loss)     1       (59 )     (10 )     (57 )
                                 
Operating expenses:                                
Research and development     1,160       2,173       4,359       6,706  
Sales and marketing     509       1,160       2,954       3,473  
General and administrative     2,155       2,028       7,432       7,189  
  Total operating expenses     3,824       5,361       14,745       17,368  
                                 
Operating loss     (3,823 )     (5,420 )     (14,755 )     (17,425 )
                                 
Gain on change in estimated fair value of contingent royalty obligation     3       127       248       68  
Finance income (expense), net     (117 )     95       (348 )     214  
Foreign currency gain (loss)     (1 )     3       (4 )     (6 )
                                 
Loss before income taxes     (3,938 )     (5,195 )     (14,859 )     (17,149 )
                                 
Income tax expense                        
                                 
Net loss   $ (3,938 )   $ (5,195 )   $ (14,859 )   $ (17,149 )
Basic and diluted loss per common share   $ (0.13 )   $ (0.18 )   $ (0.51 )   $ (0.72 )
Weighted average number of common shares outstanding, basic and diluted     30,422,265       28,716,213       29,366,154       23,896,843  

Brinks Home Security Reports Third Quarter 2020 Results

DALLAS-FORT WORTH, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) — Monitronics International, Inc. and its subsidiaries (doing business as Brinks Home Security TM), (“Brinks Home Security” or the “Company”) (OTC: SCTY) today announced results for the three months ended September 30, 2020.


Third Quarter Key Highlights1
:

  • Net revenue of $130.9 million, up 8.3% year-over- year
  • Net loss of $19.2 million, as compared to net income of $673.6 million in the prior year period, which included a one-time $702.8 million gain from restructuring
  • Adjusted EBITDA of $68.5 million, up 9.6% year-over-year
  • Successful integration of over 110,000 Protect America bulk buy accounts acquired in mid-June 2020
  • William Niles named permanent CEO on September 30, 2020

William Niles, Chief Executive Officer of Brinks Home Security, commented, “In the third quarter, we accelerated the execution of our go-forward strategic plan, with the objective of generating profitable accounts, at scale, and retaining for life. Our strategic vision is based on delivering a superior customer experience built around the Brinks Home brand and featuring a suite of premium smart home security products in both the ‘Do It For Me’ and ‘DIY’ categories.  We intend to enhance the customer experience at every touchpoint of the customer journey and improve unit economics by building a strong foundation in data analytics that, we believe, will reduce our subscriber acquisition cost, lower cost to serve and improve retention.”

“To enable this transformation, we have made several key hires across our organization to ensure we have the right leadership to drive a culture of customer centricity and execution. We also continue to take smart actions to manage our cost structure and strengthen our balance sheet. We believe we have a compelling strategic plan that will accelerate profitable growth, generate cash, and improve margins and long-term shareholder value.”


Customer & Attrition Data

The Company has two principal sales channels including its direct-to-consumer sales channel (the “Direct to Consumer Channel” or “DTC”), which offers both Do-It-Yourself and professional installation security solutions and through its exclusive authorized dealer network (the “Dealer Channel”), which provides product and installation services, as well as support to customers.  In addition, from time to time, the Company acquires accounts through negotiated bulk account acquisitions.

Accounts Added

The Company added 17,111 customers in the third quarter of 2020, as compared to 21,228 accounts for the same period in the prior year. Both the Company’s Dealer and the DTC Channels experienced year-over-year declines in customers added. The decline in the Dealer Channel was primarily due to the Company’s election to cease purchasing accounts from two dealers in the fourth quarter of 2019 and restrictions on door-to-door selling and other impacts related to the outbreak of COVID-19. The decline in the DTC Channel production was primarily due to the Company’s election to leverage more profitable organic leads. There were no bulk account acquisitions during the third quarter of 2020 or 2019.

_____________________________
1 Year-over-year comparisons based on the pro forma net revenue, net loss and adjusted EBITDA for September 30, 2019. Such pro forma adjustments to give effect to the combined successor and predecessor periods. Please see the appendix to this press release for more information.

Attrition

    Twelve Months Ended September 30,
    2020   2019
Beginning balance of accounts not subject to Earnout Payments   865,848     942,157  
Accounts acquired   75,627     84,899  
Accounts cancelled   (128,736 )   (156,047 )
Cancelled accounts guaranteed by dealer and other adjustments (a)   (5,276 )   (5,161 )
Ending balance of accounts not subject to Earnout Payments   807,463     865,848  
Accounts subject to Earnout Payments   107,929      
Ending balance of accounts   915,392     865,848  
Attrition rate – Core Unit (c)   15.4 %   17.3 %
Attrition rate – Core RMR (b) (c)   17.7 %   17.6 %

(a)   Includes cancelled accounts that are contractually guaranteed to be refunded from holdback.
(b)   The RMR of cancelled accounts follows the same definition as subscriber unit attrition as noted above. RMR attrition is defined as the RMR of cancelled accounts in a given period, adjusted for the impact of price increases or decreases in that period, divided by the weighted average of RMR for that period.
(c)   Core Unit and RMR attrition rates exclude the impact of the Protect America bulk buy, where the Company is funding the purchase price through an earnout payment structure (the “Earnout Payments”).
     

Core Unit attrition, which excludes accounts subject to earnout payments, was down for the twelve months ended September 30, 2020 as compared to the prior twelve-month period.  The decrease in the Core Unit attrition rate includes the impact of fewer customers, as a percentage of the entire base, reaching the end of their initial contract term, continued efforts around “at-risk” extensions and customer retention and the benefit of improved credit quality in the DTC Channel.

Core RMR attrition increased year-over-year due to a combination of lower RMR for accounts generated in the Company’s DTC Channel, as a minimal equipment subsidy is offered, lower production in the Dealer Channel, which typically enjoys higher RMR, and rate reductions relating to the Company’s at-risk retention program. Further, in light of COVID-19, starting in March 2020, the Company made the decision to defer taking ordinary course rate adjustments to its base, which has continued through September 30, 2020. The Company will evaluate its rate strategy going forward as circumstances warrant.


Presentation of Predecessor and Successor Financial Results

Apart from interest and amortization expense, Brinks Home Security’s operating results and key operating performance measures on a consolidated basis were not materially impacted by the reorganization of the Company in August 2019 and its application of fresh start accounting. The Company believes that certain of our consolidated operating results for the three months ended September 30, 2020 is comparable to certain operating results from the comparable prior year period.  Accordingly, the Company believes that discussing the combined non-GAAP results of operations and cash flows of the Predecessor Company and the Successor Company for the three-month period ended September 30, 2019 is useful when analyzing certain performance measures.


Three Months Ended September 30, 2020 Financial Summary2

  Successor Company           Successor Company     Predecessor Company
  Three Months Ended September 30,     Non-GAAP Combined Three Months Ended September 30,     Period from September 1, 2019 through September 30,     Period from July 1, 2019 through August 31,
  2020     2019     2019     2019
Net revenue $ 130,852       $ 120,878       $ 36,289       $ 84,589  
Cost of services 31,383       28,962       8,976       19,986  
Selling, general and administrative, including stock-based and long-term incentive compensation 31,572       32,370       11,390       20,980  
Amortization of subscriber accounts, deferred contract acquisition costs and other intangible assets 57,240       49,810       17,302       32,508  
Interest expense 20,033       34,586       7,474       27,112  
Income tax expense 717       642       204       438  
Net (loss) income (19,164 )     673,578       (10,807 )     684,385  
Adjusted EBITDA 68,512       62,502       17,144       45,358  
                             

The Company reported net revenues of $130.9 million, an increase of 8.3% as compared to the prior year period.  This improvement in net revenues includes an increase in alarm monitoring revenue of $7.0 million resulting from a higher number of average subscribers relating to the Protect America bulk acquisition and a previously disclosed $5.3 million fresh start adjustment to reduce revenue in the prior year period in connection with the Company’s emergence from bankruptcy.  Also included in the year-over-year increase in net revenues is a $3.3 million increase in product, installation and service revenue largely attributable to the Company’s continued efforts around at-risk extensions. 

RMR acquired during the quarter was $841,000, as compared to $1.0 million in the prior year period.

Cost of Services was $31.4 million, an increase of 8.4% year-over-year.  The increase is attributable to the cost to serve the incremental Protect America customers. The increase was partially offset by a decline in subscriber acquisition costs in the Company’s DTC Channel.

Selling, General and Administrative costs were $31.6 million, a decline of 2.5% year-over-year.  The decrease is primarily due to reduced subscriber acquisition costs and consulting fees on integration and implementation of company initiatives. These declines were partially offset by higher salary expense and professional fees related to the post emergence operating structure of the Company.

Net loss totaled $19.2 million as compared to a net income of $673.6 million in the prior year period.  The year-over-year change is primarily attributable to prior year gains on restructuring and reorganization and current year increases in 2G and 3G radio conversion costs and amortization expense.  These decreases were partially offset by higher revenues and lower interest expense. 

Adjusted EBITDA was $68.5 million, an increase of 9.6% year-over-year.

___________________________________
2All variances are year-over-year unless otherwise noted.


Liquidity

As of September 30, 2020, excluding a minimum liquidity requirement of $25 million under the terms of the Company’s credit agreements, the Company had total short-term liquidity of $133.7 million to fund working capital and continuing operations.  This includes $12.8 million of cash and cash equivalents and $120.9 million of remaining borrowing capacity under the $145.0 million Revolving Credit Facility.

The Company’s existing long-term debt at September 30, 2020 includes an aggregate principal balance of $987.8 million under its Takeback Loan Facility, Term Loan Facility and the Revolving Credit Facility.

Quarterly Report on Form 10-Q

Brinks Home Security’s financial statements and related footnotes will be available in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is expected to be filed with the U.S. Securities and Exchange Commission (“SEC”) on November 13, 2020.

Conference Call

Brinks Home Security will host a conference call on Thursday, November 12, 2020 at 5:00 pm ET.  Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: http://www.directeventreg.com/registration/event/7166334. Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. Alternatively, the conference call will be available via a live webcast. To access the live webcast or a replay, visit the Company’s investor relations website at https://ir.brinkshome.com/.

A replay of the call can also be accessed via phone through November 19, 2020 by dialing (800) 585-8367 from the U.S., or (416) 621-4642 from outside the U.S. The conference I.D. number is 7166334.

About Brinks Home Security

Brinks Home Security (OTC: SCTY) is one of the largest home security and alarm monitoring companies in North America.  Headquartered in the Dallas-Fort Worth area, Brinks Home Security secures over 900,000 residential and commercial customers through highly responsive, simple security solutions backed by expertly trained professionals. The Company has one of the nation’s largest networks of independent authorized dealers and agents – providing products and support to customers in the U.S., Canada, and Puerto Rico – as well as direct-to-consumer sales of DIY and professionally installed products.

Forward Looking Statements

This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about business strategies, market potential and expansion, the success of new products and services, the launch of Brinks Home Security’s consumer financing solution; the anticipated benefits of the Brinks Home Security’s rebranding; customer retention; account creation and related cost; anticipated account generation; future financial performance; debt refinancing; recovery of insurance proceeds and other matters that are not historical facts. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, possible changes in market acceptance of our services, technological innovations in the alarm monitoring industry, competitive issues, continued access to capital on terms acceptable to us, our ability to capitalize on acquisition opportunities, general market and economic conditions, including global economic concerns due to the COVID-19 outbreak, and changes in law and government regulations. These forward-looking statements speak only as of the date of this press release, and we expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Please refer to the publicly filed documents of Monitronics International, Inc., including the most recent Forms 10-K and 10-Q for additional information about us and about the risks and uncertainties related to our business which may affect the statements made in this press release.

1) Adjusted EBITDA and the Non-GAAP Combined Three Months Ended September 30, 2019 financials are non-GAAP financial measures. See the Appendix of this press release for related disclosures and calculations.

Contact:

Erica Bartsch
Sloane & Company
212-446-1875
[email protected]

 
MONITRONICS INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

Amounts in thousands, except share amounts
   
  Successor Company
  September 30,

2020
  December 31,

2019

Assets
     
Current assets:      
Cash and cash equivalents $ 12,759     $ 14,763  
Restricted cash 133     238  
Trade receivables, net of allowance for doubtful accounts of $2,759 in 2020 and $3,828 in 2019 10,854     12,083  
Inventories, net 6,878     5,242  
Prepaid and other current assets 20,387     19,953  
Total current assets 51,011     52,279  
Property and equipment, net of accumulated depreciation of $13,796 in 2020 and $3,777 in 2019 41,516     42,096  
Subscriber accounts and deferred contract acquisition costs, net of accumulated amortization of $208,387 in 2020 and $61,771 in 2019 1,089,198     1,064,311  
Dealer network and other intangible assets, net of accumulated amortization of $25,748 in 2020 and $7,922 in 2019 118,952     136,778  
Goodwill     81,943  
Deferred income tax asset, net 684     684  
Operating lease right-of-use asset 18,345     19,277  
Other assets 18,651     21,944  
Total assets $ 1,338,357     $ 1,419,312  

Liabilities and Stockholders’ Equity
     
Current liabilities:      
Accounts payable $ 13,369     $ 16,869  
Other accrued liabilities 45,806     24,954  
Deferred revenue 11,065     12,008  
Holdback liability 8,583     8,191  
Current portion of long-term debt 8,225     8,225  
Total current liabilities 87,048     70,247  
Non-current liabilities:      
Long-term debt 979,550     978,219  
Long-term holdback liability 1,761     2,183  
Operating lease liabilities 15,648     16,195  
Other liabilities 66,989     6,390  
Total liabilities 1,150,996     1,073,234  
Commitments and contingencies      
Stockholders’ equity:      
Preferred stock, $0.01 par value.  Authorized 5,000,000 shares; no shares issued      
Common stock, $0.01 par value.  Authorized 45,000,000 shares; issued and outstanding 22,500,000 shares at both September 30, 2020 and December 31, 2019 225     225  
Additional paid-in capital 379,175     379,175  
Accumulated deficit (189,779 )   (33,331 )
Accumulated other comprehensive (loss) income, net (2,260 )   9  
Total stockholders’ equity 187,361     346,078  
Total liabilities and stockholders’ equity $ 1,338,357     $ 1,419,312  
               

 
MONITRONICS INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Amounts in thousands, except shares and per share amounts
         
  Successor Company     Predecessor Company
  Three Months Ended September 30,   Period from September 1, 2019 through September 30,     Period from July 1, 2019 through August 31,
  2020   2019     2019
Net revenue $ 130,852     $ 36,289       $ 84,589  
Operating expenses:            
Cost of services 31,383     8,976       19,986  
Selling, general and administrative, including stock-based and long-term incentive compensation 31,572     11,390       20,980  
Radio conversion costs 5,612     825       931  
Amortization of subscriber accounts, deferred contract acquisition costs and other intangible assets 57,240     17,302       32,508  
Depreciation 3,459     925       1,073  
  129,266     39,418       75,478  
Operating income (loss) 1,586     (3,129 )     9,111  
Other (income) expense:            
Gain on restructuring and reorganization, net           (702,824 )
Interest expense 20,033     7,474       27,112  
  20,033     7,474       (675,712 )
(Loss) income before income taxes (18,447 )   (10,603 )     684,823  
Income tax expense 717       204       438  
Net (loss) income (19,164 )   (10,807 )     684,385  
Other comprehensive loss:            
Unrealized loss on derivative contracts, net (475 )          
Total other comprehensive loss, net of tax (475 )          
Comprehensive (loss) income $ (19,639 )   $ (10,807 )     $ 684,385  
             
Basic and diluted income per share:            
Net loss $ (0.85 )   $ (0.48 )     $  
             
Weighted average Common shares – basic and diluted 22,500,000     22,500,000        
Total issued and outstanding Common shares at period end 22,500,000     22,500,000        
                   

 
MONITRONICS INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Amounts in thousands, except shares and per share amounts
         
  Successor Company     Predecessor Company
  Nine Months Ended September 30,   Period from September 1, 2019 through September 30,     Period from January 1, 2019 through August 31,
  2020   2019     2019
Net revenue $ 374,235     $ 36,289       $ 342,286  
Operating expenses:            
Cost of services 87,017     8,976       75,286  
Selling, general and administrative, including stock-based and long-term incentive compensation 108,566     11,390       80,365  
Radio conversion costs 14,103     825       931  
Amortization of subscriber accounts, deferred contract acquisition costs and other intangible assets 164,889     17,302       130,791  
Depreciation 10,019     925       7,348  
Goodwill impairment 81,943            
  466,537     39,418       294,721  
Operating (loss) income (92,302 )   (3,129 )     47,565  
Other (income) expense:            
Gain on restructuring and reorganization, net           (669,722 )
Interest expense 60,582     7,474       105,081  
Realized and unrealized loss, net on derivative financial instruments           6,804  
Refinancing expense           5,214  
  60,582     7,474       (552,623 )
(Loss) income before income taxes (152,884 )   (10,603 )     600,188  
Income tax expense 1,937       204       1,775  
Net (loss) income (154,821 )   (10,807 )     598,413  
Other comprehensive loss:            
Unrealized loss on derivative contracts, net (2,269 )         (940 )
Total other comprehensive loss, net of tax (2,269 )         (940 )
Comprehensive (loss) income $ (157,090 )   $ (10,807 )     $ 597,473  
             
Basic and diluted income per share:            
Net loss $ (6.88 )   $ (0.48 )     $  
             
Weighted average Common shares – basic and diluted 22,500,000     22,500,000        
Total issued and outstanding Common shares at period end 22,500,000     22,500,000        
                   

Adjusted EBITDA

We evaluate the performance of our operations based on financial measures such as revenue and “Adjusted EBITDA.” Adjusted EBITDA is a non-GAAP financial measure and is defined as net income (loss) before interest expense, interest income, income taxes, depreciation, amortization (including the amortization of subscriber accounts, dealer network and other intangible assets), restructuring charges, stock-based compensation, and other non-cash or non-recurring charges. We believe that Adjusted EBITDA is an important indicator of the operational strength and performance of our business. In addition, this measure is used by management to evaluate operating results and perform analytical comparisons and identify strategies to improve performance. Adjusted EBITDA is also a measure that is customarily used by financial analysts to evaluate the financial performance of companies in the security alarm monitoring industry and is one of the financial measures, subject to certain adjustments, by which our covenants are calculated under the agreements governing our debt obligations. Adjusted EBITDA does not represent cash flow from operations as defined by generally accepted accounting principles in the United States (“GAAP”), should not be construed as an alternative to net income or loss and is indicative neither of our results of operations nor of cash flows available to fund all of our cash needs. It is, however, a measurement that we believe is useful to investors in analyzing our operating performance. Accordingly, Adjusted EBITDA should be considered in addition to, but not as a substitute for, net income, cash flow provided by operating activities and other measures of financial performance prepared in accordance with GAAP. As companies often define non-GAAP financial measures differently, Adjusted EBITDA as calculated by Monitronics should not be compared to any similarly titled measures reported by other companies.

The following table provides a reconciliation of Net (loss) income to total Adjusted EBITDA for the periods indicated (amounts in thousands):

  Successor Company           Successor Company     Predecessor Company
  Three Months Ended September 30,     Non-GAAP Combined Three Months Ended September 30,     Period from September 1, 2019 through September 30,     Period from July 1, 2019 through August 31,
  2020     2019     2019     2019
Net (loss) income $ (19,164 )     $ 673,578       $ (10,807 )     $ 684,385  
Amortization of subscriber accounts, deferred contract acquisition costs and other intangible assets 57,240       49,810       17,302       32,508  
Depreciation 3,459       1,998       925       1,073  
Radio conversion costs 5,612       1,756       825       931  
Stock-based compensation       266             266  
Long-term incentive compensation 2       107       67       40  
Severance expense (a) 47                    
Integration / implementation of company initiatives 566       2,583       1,154       1,429  
Gain on restructuring and reorganization, net       (702,824 )           (702,824 )
Interest expense 20,033       34,586       7,474       27,112  
Income tax expense 717       642       204       438  
Adjusted EBITDA $ 68,512       $ 62,502       $ 17,144       $ 45,358  
                     

Expensed Subscriber acquisition costs, net
                   
Gross subscriber acquisition costs (b) $ 3,102       $ 8,041       $ 2,499       $ 5,542  
Revenue associated with subscriber acquisition costs (1,527 )     (1,925 )     (534 )     (1,391 )
Expensed Subscriber acquisition costs, net $ 1,575       $ 6,116       $ 1,965       $ 4,151  

_____________________

(a)   Severance expense related to transitioning executive leadership in 2020.
(b)   Gross subscriber acquisition costs for the three months ended September 30, 2019 has been restated from $9,710,000 to $8,041,000 due to allocation adjustments made to align with current period presentation of expensed subscriber acquisition costs.
     

The following table provides a reconciliation of Net (loss) income to total Adjusted EBITDA for the periods indicated (amounts in thousands):

  Successor Company           Successor Company     Predecessor Company
  Nine Months Ended September 30,     Non-GAAP Combined Nine Months Ended September 30,     Period from September 1, 2019 through September 30,     Period from January 1, 2019 through August 31,
  2020     2019     2019     2019
Net (loss) income $ (154,821 )     $ 587,606       $ (10,807 )     $ 598,413  
Amortization of subscriber accounts, deferred contract acquisition costs and other intangible assets 164,889       148,093       17,302       130,791  
Depreciation 10,019       8,273       925       7,348  
Radio conversion costs 14,103       1,756       825       931  
Stock-based compensation       42             42  
Long-term incentive compensation 403       657       67       590  
LiveWatch acquisition contingent bonus charges       63             63  
Legal settlement reserve (related insurance recovery) (700 )     (4,800 )           (4,800 )
Severance expense (a) 4,289                    
Integration / implementation of company initiatives 8,710       5,997       1,154       4,843  
Goodwill impairment 81,943                    
Gain on restructuring and reorganization, net       (669,722 )           (669,722 )
Interest expense 60,582       112,555       7,474       105,081  
Realized and unrealized loss, net on derivative financial instruments       6,804             6,804  
Refinancing expense       5,214             5,214  
Income tax expense 1,937       1,979       204       1,775  
Adjusted EBITDA $ 191,354       $ 204,517       $ 17,144       $ 187,373  
                     

Expensed Subscriber acquisition costs, net
                   
Gross subscriber acquisition costs (b) $ 14,693       $ 22,818       $ 2,499       $ 20,319  
Revenue associated with subscriber acquisition costs (4,831 )     (6,021 )     (534 )     (5,487 )
Expensed Subscriber acquisition costs, net $ 9,862       $ 16,797       $ 1,965       $ 14,832  

_____________________

(a)   Severance expense related to transitioning executive leadership in 2020.
(b)   Gross subscriber acquisition costs for the nine months ended September 30, 2019 has been restated from $27,902,000 to $22,818,000 due to allocation adjustments made to align with current period presentation of expensed subscriber acquisition costs.
     

Yield10 Bioscience Announces Third Quarter 2020 Financial Results

WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and nine months ended September 30, 2020.

“We are very pleased with our strong progress across multiple fronts in the third quarter and beyond,” said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. “We completed harvesting for our 2020 field test program to evaluate novel yield and compositional traits in Camelina and canola conducted in the United States and Canada, and look forward to reporting data in the fourth quarter of 2020 through early 2021.  We plan to evaluate seed yield, oil content, PHA content and other metrics of the traits which will also inform our priorities for trait evaluation in 2021.”

“We are very pleased to have recently announced our collaboration with Rothamsted Research for the advancement of technology that enables the land-based, sustainable production of omega-3 (DHA + EPA) oils for use in aquaculture. There is a significant market opportunity for the development of plant-based feeding solutions for the production of fish, particularly salmon, for human consumption. The technology has demonstrated the DHA + EPA omega-3 trait in Camelina and is highly complementary to our own Camelina Platform. The key objective is to support Rothamsted’s continued research as they further optimize the DHA + EPA omega-3 trait as a drop-in replacement for southern hemisphere fish oil and conduct field tests and feeding studies.  Yield10 will develop a strategic business plan with an initial focus on South America.”

“In addition to executing our field test program and advancing our Camelina business plan, we also shored up our balance sheet in the third quarter with the closing of a public offering and concurrent private placement of common stock that raised $5.7 million in gross proceeds to Yield10. As we approach year end 2020, we remain focused on generating proof points for our traits in development and on advancing business discussions around our Camelina business plan,” Dr. Peoples concluded.

Recent Accomplishments Towards Achieving 2020 Milestones

Advance the Camelina Business Plan.  Yield10 recently signed exclusive research collaboration and commercial option agreements with Rothamsted Research to evaluate advanced technology for producing omega-3 nutritional oils in Camelina. The Rothamsted technology could enable the sustainable, plant-based production of DHA+EPA omega-3 nutritional oil that closely mimics the composition of southern hemisphere fish oil, an important ingredient in aquaculture feed for salmon and other species.

In the third quarter, Yield10 began field tests of internally developed double haploid varieties of winter Camelina as part of a program to develop Camelina as a commercial crop. Yield10 also harvested 50 acres of wild-type spring Camelina to begin building relationships with growers, developing agronomic guidelines for successfully growing Camelina, and producing Camelina oil and meal for sampling to potential customers.

Generate Proof Points for Novel Traits in Camelina and Canola. Yield10 completed the harvest of the Company’s 2020 Field Tests to evaluate a series of traits in Camelina and canola. Key studies include the evaluation of C3004 in Camelina as well as tests of traits to boost seed yield and/or oil content in Camelina and canola. These studies, for the first time, include field testing of a novel trait to produce PHA in the seed of Camelina. The purpose of this activity is to determine the suitability of these first generation PHA Camelina lines for scale-up and PHA product prototyping in 2021. Yield10 expects that data from the studies will begin to become available in the fourth quarter of 2020 and into early 2021.

Advance the Corn Development Program. Continued to execute field work to create hybrid corn lines for field testing including the start of a second growth cycle in the third quarter for corn lines deployed with Yield10 traits. Yield10 plans to seek a research license partner for corn.

Manage its Financial Profile and Strengthen the Balance Sheet. Yield10’s financial results for the nine-month period ended September 30, 2020 are on track with internal estimates. Yield10 strengthened its balance sheet in the third quarter of 2020 based on raising approximately $5.7 million in gross proceeds from the issuance of common stock in offerings completed on August 26, 2020.

COVID-19 Impact on Operations. The Company has implemented business continuity plans to address the COVID-19 pandemic and minimize disruptions to ongoing operations. To date, despite the pandemic, we have been able to move forward with the operational steps required to execute our 2020 field trials in Canada and the United States. It is possible, however, that any potential future closures of our research facilities, should they continue for an extended time period, could adversely impact our anticipated time frames for evaluating and/or reporting data from our field trials and other work we have planned to accomplish during 2020 and beyond.

THIRD QUARTER 2020 FINANCIAL OVERVIEW

Cash Position

Yield10 Bioscience is managed with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives.

Net cash used by operating activities during the third quarter of 2020 was $2.1 million compared to $1.4 million used in the third quarter of 2019. Yield10 ended the third quarter of 2020 with $11.8 million in unrestricted cash, cash equivalents and short-term investments. The Company continues to estimate total net cash usage during the full year 2020 within a range of $8.5 – $9.0 million.

The Company’s present capital resources are expected to fund its planned operations through the end of 2021. Yield10’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, including public or private equity financing, secured or unsecured debt financing, and receipt of additional government research grants, as well as licensing or other collaborative arrangements.

Grant revenue for both the third quarter of 2020 and 2019 was $0.2 million, respectively. Research and development expenses were $1.3 million and $1.2 million for the third quarters of 2020 and 2019, respectively. General and administrative expenses increased to $1.1 million during the third quarter of 2020 from $1.0 million during the third quarter of 2019. The quarter-over-quarter increases in operating expense are primarily a result of the Company recording pro rata estimates for 2020 employee bonuses that are expected to be paid during the first quarter of 2021. In 2019, Yield10 did not accrue for bonuses until the fourth quarter.

Yield10 reported a loss from operations of $2.2 million for the quarter ended September 30, 2020 compared to a loss from operations of $2.0 million for the same quarter of 2019. The Company reported a total net loss after income tax expense of $2.2 million, or $0.87 per share for the three months ended September 30, 2020, in comparison to a total net loss after income taxes of $2.0 million, or $6.33 per share, for the three months ended September 30, 2019.

For the nine months ending September 30, 2020, the Company reported a net operating loss after taxes of $7.6 million, or $3.69 per share compared to a net operating loss after taxes of $6.1 million, or $20.64 per share for the nine months ending September 30, 2019. Year to date grant revenue earned through September 30, 2020 and September 30, 2019 was $0.6 million and $0.7 million, respectively. Research and development expenses were $3.9 million during the nine months ended September 30, 2020, compared to $3.6 million for the nine months ended September 30, 2019, and general and administrative expenses were $3.7 million and $3.2 million during the nine months ended September 30, 2020 and September 30, 2019, respectively. During the nine months ended September 30, 2020, the Company recognized $0.3 million in loan forgiveness income related to a Paycheck Protection Program Loan (“PPP Loan”) issued to the Company under the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). Yield10 utilized the entire PPP Loan amount of $0.3 million for qualifying payroll and other expenses during the second quarter of 2020 and considers it reasonably certain that its application for loan forgiveness under the CARES Act will be approved.

Reverse Stock Split

Yield10 completed a 1-for-40 reverse stock split of its common stock on January 15, 2020, in order to regain compliance with the Nasdaq Stock Market minimum bid price qualification of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2). In accordance with applicable accounting guidance, all share amounts, per share data, share prices and conversion rates set forth in the Company’s condensed consolidated financial statements for the three and nine months ending September 30, 2020 and September 30, 2019, including those presented in this earnings release, have been retroactively adjusted to reflect the reverse stock split.

Conference Call Information

Yield10 Bioscience management will host a conference call at 4:30 p.m. (ET) today to discuss the third quarter 2020 results. The Company also will provide an update on the business and answer questions from the investor community. A live webcast of the call with slides can be accessed through the Company’s website at www.yield10bio.com in the investor relations events section. To participate in the call, dial toll-free 877-709-8150 or 201-689-8354 (international).

To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 13711239. The replay will be available until November 26, 2020. In addition, the webcast will be archived on the Company’s website in the investor relations events section.

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations to improve crop yields and enhance sustainable global food security. The Company utilizes its proprietary “GRAIN“ (Gene Ranking Artificial Intelligence Network) gene discovery platform to identify gene targets to improve yield performance and value in major commercial food and feed crops. Yield10 uses its Camelina oilseed platform to rapidly evaluate and field test new trait leads enabling the translation of promising new traits into the major commercial crops. As a path toward commercialization, Yield10 is pursuing a partnering approach with agricultural companies to drive new traits into development in crops such as canola, soybean and corn. The Company is also developing Camelina as a platform crop for producing nutritional oils and specialty products such as PHA biomaterials for use in water treatment and bioplastic applications. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visit www.yield10bio.com, or follow the Company on Twitter, Facebook and LinkedIn. (YTEN-E)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding Yield10’s cash position, cash forecasts and runway, ability to obtain sufficient financing to continue operating, expectations related to research and development activities, intellectual property, the expected regulatory path for traits, reproducibility of data from field tests, the timing of completion of additional greenhouse and field test studies, the timing for reporting data from the 2020 field tests and the outcomes of those tests, the signing of research licenses and collaborations, including whether the objectives of those collaborations will be met, whether the Company will be able to generate proof points for traits in development and advance business discussions around its Camelina business plan, the potential impact on operations of the COVID-19 pandemic, and value creation as well as the overall progress of Yield10 Bioscience, Inc., constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience’s filings with the Securities and Exchange Commission. Yield10 Bioscience assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Contacts:

Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, [email protected]

Investor Relations:
Bret Shapiro, (561) 479-8566, [email protected]
Managing Director, CORE IR

Media Inquiries:
Eric Fischgrund, [email protected]
FischTank PR

(FINANCIAL TABLES FOLLOW)

YIELD10 BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

UNAUDITED

(In thousands, except share and per share amounts)

  Three Months Ended 

September 30,
  Nine Months Ended 

September 30,
  2020   2019   2020   2019
Revenue:                              
Grant revenue $ 204     $ 224     $ 604     $ 666  
Total revenue   204       224       604       666  
                               
Expenses:                              
Research and development   1,300       1,232       3,939       3,646  
General and administrative   1,098       990       3,664       3,201  
Total expenses   2,398       2,222       7,603       6,847  
Loss from operations   (2,194 )     (1,998 )     (6,999 )     (6,181 )
                               
Other income (expense):                              
Change in fair value of warrants               (957 )      
Loan forgiveness income               333        
Other income (expense), net   37       16       85       68  
Total other income (expense)   37       16       (539 )     68  
Net loss before income tax expense   (2,157 )     (1,982 )     (7,538 )     (6,113 )
Income tax expense   (11 )           (26 )      
Net loss $ (2,168 )   $ (1,982 )   $ (7,564 )   $ (6,113 )
                               
Basic and diluted net loss per share $ (0.87 )   $ (6.33 )   $ (3.69 )   $ (20.64 )
                               
Number of shares used in per share calculations:                              
Basic and diluted   2,492,274       312,952       2,050,726       296,139  

YIELD10 BIOSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

UNAUDITED

(In thousands, except share and per share amounts)

  September 30, 

2020
  December 31, 

2019
Assets              
Current Assets:              
Cash and cash equivalents $ 2,995     $ 5,417  
Short-term investments   8,794       5,700  
Accounts receivable   148       72  
Unbilled receivables   56       20  
Prepaid expenses and other current assets   368       475  
Total current assets   12,361       11,684  
Restricted cash   254       332  
Property and equipment, net   935       1,243  
Right-of-use assets   2,796       3,141  
Other assets   300       318  
Total assets $ 16,646     $ 16,718  
               
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)              
Current Liabilities:              
Accounts payable $ 103     $ 279  
Accrued expenses   930       1,326  
Lease liabilities   443       602  
Total current liabilities   1,476       2,207  
Lease liabilities, net of current portion   3,283       3,619  
Warrant liability         14,977  
Other long-term liabilities   15        
Total liabilities   4,774       20,803  
Commitments and contingencies              
Series B Convertible Preferred Stock ($0.01 par value per share); 0 and 5,750 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively          
Stockholders’ Equity (Deficit):              
Series A Convertible Preferred Stock ($0.01 par value per share); 0 shares and 796 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively          
Common stock ($0.01 par value per share); 60,000,000 shares authorized at September 30, 2020 and December 31, 2019; 3,330,778 and 933,423 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively   33       9  
Additional paid-in capital   384,465       360,926  
Accumulated other comprehensive loss   (168 )     (126 )
Accumulated deficit   (372,458 )     (364,894 )
Total stockholders’ equity (deficit)   11,872       (4,085 )
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $ 16,646     $ 16,718  

YIELD10 BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED

(In thousands)

  Nine Months Ended 

September 30,
  2020
  2019
Cash flows from operating activities              
Net loss $ (7,564 )   $ (6,113 )
Adjustments to reconcile net loss to cash used in operating activities:              
Depreciation   137       150  
Change in fair value of warrants   957        
Loss on disposal of fixed assets   206        
Charge for 401(k) company common stock match   95       73  
Stock-based compensation   506       406  
Non-cash lease expense   345       456  
Deferred income tax provision   33        
Changes in operating assets and liabilities:              
Accounts receivable   (76 )     23  
Unbilled receivables   (36 )     (17 )
Prepaid expenses and other assets   92       217  
Accounts payable   (228 )     (66 )
Accrued expenses   (324 )     48  
Lease liabilities   (495 )     (622 )
Other liabilities   15        
Net cash used for operating activities   (6,337 )     (5,445 )
               
Cash flows from investing activities              
Purchase of property and equipment   (42 )     (12 )
Proceeds from sale of property and equipment   10        
Purchase of short-term investments   (6,290 )     (1,000 )
Proceeds from the sale and maturity of short-term investments   3,197       3,746  
Net cash (used for) provided by investing activities   (3,125 )     2,734  
               
Cash flows from financing activities              
Proceeds from warrants exercised   1,658        
Proceeds from public and private offerings, net of issuance costs   5,367       2,583  
Taxes paid on employees’ behalf related to vesting of stock awards   (17 )     (4 )
Net cash provided by financing activities   7,008       2,579  
               
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (46 )     (14 )
               
Net decrease in cash, cash equivalents and restricted cash   (2,500 )     (146 )
Cash, cash equivalents and restricted cash at beginning of period   5,749       3,355  
Cash, cash equivalents and restricted cash at end of period $ 3,249     $ 3,209  
               
Supplemental disclosure of non-cash information:              
Offering costs remaining in accrued expenses $ 63     $ 41  

 

Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2020


Guardion


A


lso


Provides Corporate Update

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace, announced financial results for the three months and nine months ended September 30, 2020, and is also providing a corporate update.

Financial and corporate highlights for the three months and nine months ended September 30, 2020 include the following:

  • Total revenue was approximately $253,000 for the three months ended September 30, 2020, as compared to approximately $161,000 for the three months ended September 30, 2019, an increase of 57%.
  • Medical foods sales are up 26% for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019.
  • Medical devices sales are up 147% for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019.
  • Net loss for the three months ended September 30, 2020 was approximately ($2,143,000) or ($0.02) per share, as compared to a net loss of approximately ($2,385,000) or ($0.07) per share for the three months ended September 30, 2019.
  • Cash balance at September 30, 2020 was approximately $9,800,000.
  • Ho Wah Genting Berhad (“HWGB”), the Company’s distributor in Malaysia, has received product registration approval from the Malaysian National Pharmaceutical Regulatory Agency (“NPRA”) for Astramern Nutra V, an immune support dietary supplement designed and produced by Guardion; approval for Astramern Nutra H, an herb formulation that HWGB intends to market together with Astramern Nutra V, continues to be pending with the Malaysian NPRA.
  • Publication of promising new data in the journal Nutrients (published   October 26, 2020), which compared the efficacy of the Company’s Lumega-Z® to the current standard of care, the AREDS-2 soft gel supplement (marketed under the PreserVision® brand by Bausch + Lomb) in patients with vision problems associated with eye disease. Lumega-Z® demonstrated statistically significant vision improvements in both eyes at six months (p < 0.001), and a positive linear trend with treatment time (p < 0.001), with benefits visible after just three months; whereas the AREDS-2 supplement gel cap formulation provided no significant change (p > 0.05).
  • Initiation of investigator-initiated clinical trials designed to evaluate the impact of Lumega-Z® on the restoration of the macular pigment and its relationship to the stabilization or recovery of vision in patients with eye disease. It is believed that depletion of the macular pigment at the back of the eye is a risk factor for vision problems related to age-related macular degeneration (“AMD”), glaucoma and other serious eye diseases.
  • Guardion retained the investment banking firm Corporate Finance Associates (“CFA”) to act as its exclusive financial advisor to assist management and the Board of Directors in the identification and evaluation of strategic transactions to enhance shareholder value.
  • At the Company’s Annual Meeting of Shareholders held on October 29, 2020, shareholders approved all four matters presented for approval.
  • Trademark for “NutriGuard” issued on October 27, 2020 by the U.S. Patent and Trademark Office under Class 5 – nutritional dietary supplements.

David Evans, Ph.D., Guardion’s interim President and Chief Executive Officer, and Chief Science Officer, commented, “As we continue to develop our investment into clinical research to build strong differentiated brand claims, we are entering the commercial phase of our business development process. Despite a challenging environment with the COVID-19 pandemic, which has slowed our progress both in terms of connecting directly with doctors and consumers, as well as conducting day-to-day business, sales continue to be up year-over-year. Over the course of this pandemic, it has become increasingly clear that there are multiple business opportunities for Guardion to explore, including enhancing our digital distribution channels and e-commerce platform and expanding our international distribution opportunities. In addition, we are working closely with CFA to identify and evaluate strategic transactions and opportunities to enhance shareholder value.”

Dr. Evans concluded, “We continue to receive third party validation of our products, including recently published studies, in the journal Nutrients, showing superior efficacy of our proprietary formulation, Lumega-Z®, in terms of both absorption level and improvement in visual function, versus PreserVision®, the industry leading AREDS-2 gel cap product formulation. These results clearly support our brand messaging and offer an evidenced-based foundation to support our evolving product development strategies. We will continue our commitment to scientific and clinical validation of our proprietary products and to report on our results to our shareholders as this information occurs.”

Results of Annual Meeting of Shareholders
and Nasdaq Delisting Issue

On October 29, 2020, the Company held its annual meeting of shareholders (the “Meeting”). At the Meeting, the Company’s shareholders approved all four proposals, including extending the discretionary authority previously granted to the Board of Directors to effect a “reverse stock split,” at a specific ratio within a range of no split and one-for-thirty (1-for-30), with the exact ratio to be determined by the Board of Directors in its sole discretion on or before October 29, 2021.

Since the Company does not intend to execute a reverse stock split prior to November 30, 2020, Guardion expects to receive a notice of delisting from The Nasdaq Capital Market (“Nasdaq”) shortly after November 30, 2020 because the trading price of the Company’s common stock does not meet the $1.00 per share minimum bid price requirement.

The Company intends to appeal any notice of delisting that Nasdaq issues after November 30, 2020 to request a further extension of time (not to exceed 180 days from the date of the notice of delisting) to regain compliance with the $1.00 minimum bid price requirement. Such temporary relief would allow the Company additional time to execute on its business initiatives to generate greater shareholder value, which the Company hopes would then be reflected by an increase in the price of the Company’s common stock. During the appeal process, the Company’s common stock will continue to be listed on Nasdaq.

A permanent delisting from Nasdaq could adversely impact the liquidity of the Company’s common stock and limit the ability of the Company to raise additional capital in the future.

Financial Results

Three Months Ended September 30, 2020

Total revenue for the three months ended September 30, 2020 increased by approximately 57% to approximately $253,000, as compared total revenue for the three months ended September 30, 2019 of approximately $161,000, primarily due to increased sales of medical foods and nutraceuticals and medical devices in the current period.

Operating expenses for the three months ended September 30, 2020 decreased by approximately 8% to approximately $2,291,000 as compared to operating expenses for the three months ended September 30, 2019 of approximately $2,503,000, primarily due to a decrease in selling and marketing expenses in the current period.

Operating loss for the three months ended September 30, 2020 decreased by approximately $260,000 to approximately ($2,152,000), as compared to the operating loss for the three months ended September 30, 2019 of approximately ($2,412,000). Net loss for the three months ended September 30, 2020 was approximately ($2,143,000), or ($0.02) per share, as compared to a net loss of approximately ($2,385,000), or ($0.07) per share, for the three months ended September 30, 2019.

Nine Months Ended September 30, 2020

Total revenue for the nine months ended September 30, 2020 increased by approximately 154% to approximately $1,690,000, as compared to total revenue for the nine months ended September 30, 2019 of approximately $665,000. This increase was primarily due to a large initial test order of a nutraceutical product placed by the Company’s Malaysian distributor of $890,000 that was recorded during the three months ended June 30, 2020 and increased sales of medical food product lines, partially offset by a decrease in medical device sales which were affected by the impact of COVID-19 closures during the nine months ended September 30, 2020.

Operating expenses for the nine months ended September 30, 2020 decreased by approximately 12% to approximately $6,018,000, as compared to operating expenses for the nine months ended September 30, 2019 of approximately $6,813,000, primarily due to a reduction of approximately $965,000 in stock-based compensation cost related to a reversal of stock-based compensation as a result of the resignation of the Company’s former President and Chief Executive Officer in June 2020.

Operating loss for the nine months ended September 30, 2020 decreased by approximately $1,214,000 to approximately ($5,196,000), as compared to the operating loss for the nine months ended September 30, 2019 of approximately ($6,410,000). Net loss for the nine months ended September 30, 2020 was approximately ($5,198,000), or ($0.06) per share, as compared to a net loss of approximately ($6,823,000), or ($0.26) per share, for the nine months ended September 30, 2019.

About
Guardion
Health Sciences

Guardion is a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace. Located in San Diego, California, the Company combines targeted nutrition with innovative, evidence-based diagnostic technology. Guardion boasts impressive Scientific and Medical Advisory Boards. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov).
The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
[email protected] 

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
[email protected] 

Guardion Health Sciences, Inc.
Condensed Consolidated Balance Sheets
 
  September 30, 2020     December 31, 2019  
  (Unaudited)        
Assets              
               
Current assets              
Cash $ 9,795,441     $ 11,115,502  
Accounts receivable   22,849       78,337  
Inventories, net   1,284,173       310,941  
Prepaid expenses   231,621       362,938  
               
Total current assets   11,334,084       11,867,718  
               
Deposits   11,751       11,751  
Property and equipment, net   305,600       374,638  
Right-of-use asset, net   457,677       572,714  
Intangible assets   50,000       50,000  
               
Total assets $ 12,159,11
2
    $ 12,876,821  
               
Liabilities and Stockholders’ Equity              
               
Current liabilities              
Accounts payable $ 576,890     $ 70,291  
Accrued expenses   182,597       175,052  
Due to former officer   230,208        
Derivative warrant liability   7,519       13,323  
Lease liability – current   159,962       151,568  
Total current liabilities   1,157,176       410,234  
               
Lease liability – long-term   313,909       434,747  
               
Total liabilities   1,471,085       844,981  
               
Commitments and contingencies              
               
Stockholders’ Equity              
               
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued
and outstanding
         
Common stock, $0.001 par value; 250,000,000 shares authorized;
88,327,312 and 74,982,562 shares issued and outstanding at
September 30, 2020 and December 31, 2019, respectively
  88,327       74,983  
Additional paid-in capital   61,308,938       57,468,528  
Accumulated deficit   (50,709,238 )     (45,511,671 )
               
Total stockholders’ equity   10,688,02
7
      12,031,840  
               
Total liabilities and stockholders’ equity $ 12,159,11
2
    $ 12,876,821  

Guardion Health Sciences, Inc.
Condensed Consolidated Statements of Operations
 
  Three Months Ended

September 30,
    Nine Months Ended

September 30,
 
  2020     2019     2020     2019  
  (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Revenue                              
Medical foods and nutraceuticals $ 142,556     $ 112,957     $ 1,446,584     $ 317,338  
Medical devices   110,632       44,705       237,136       337,531  
Other         3,500       6,100       9,800  
Total revenue   253,188       161,162       1,689,820       664,669  
                               
Cost of goods sold                              
Medical foods and nutraceuticals   68,956       41,655       764,245       120,608  
Medical devices   45,157       27,922       101,077       136,958  
Other         1,422       2,478       3,981  
Total cost of goods sold   114,113       70,999       867,800       261,547  
                               
Gross profit   139,075       90,163       822,020       403,122  
                               
Operating expenses                              
Research and development   34,034       31,897       109,803       138,613  
Sales and marketing   167,213       448,387       1,175,126       1,246,846  
General and administrative   2,070,998       2,022,367       5,299,696       5,427,573  
Costs related to resignation of former officer
(including the reversal of previously recognized stock
compensation expense of $965,295 during the nine months ended
September 30, 2020)
              (615,936 )      
Loss on sale of equipment   18,500             18,500        
Impairment loss on equipment               30,948        
                               
Total operating expenses   2,290,745       2,502,651       6,018,137       6,813,032  
                               
Loss from operations   (2,151,670 )     (2,412,488 )     (5,196,117 )     (6,409,910 )
                               
Other (income) expense:                              
Interest expense   3,716       4,205       7,254       255,842  
Finance cost upon issuance of warrants                     415,955  
Change in fair value of derivative warrants   (11,892 )     (31,322 )     (5,804     (259,154 )
                               
Total other (income) expense   8,176       (27,117)       1,450       412,643  
                               
Net loss $ (2,143,494 )   $ (2,385,371 )   $ (5,197,567 )   $ (6,822,553 )
                               
Net loss per common share – basic and diluted $ (0.02 )   $ (0.07 )   $ (0.06 )   $ (0.26 )
Weighted average common shares outstanding – basic and diluted   88,320,523       36,035,309       84,530,367       26,483,713  

Guardion Health Sciences, Inc.
Operations by Segment (Unaudited)
 
  For the Three Months Ended September 30, 2020  
  Corporate     Medical
Foods and
Nutraceuticals
    Medical
Devices
  Total  
                     
Revenue $     $ 142,556     $ 110,632   $ 253,188  
                             
Cost of goods sold         68,956       45,157     114,113  
                             
Gross profit         73,600       65,475     139,075  
                             
Operating expenses   1,202,402       1,081,897       6,446     2,290,745  
                             
(Loss) income from operations $ (1,202,402 )   $ (1,008,296 )   $ 59,028   $ (2,151,670 )

  For the Nine Months Ended September 30, 2020  
  Corporate     Medical
Foods and
Nutraceuticals
    Medical
Devices
    Total  
                       
Revenue $ 6,100     $ 1,446,584     $ 237,136     $ 1,689,820  
                               
Cost of goods sold   2,477       764,246       101,077       867,800  
                               
Gross profit   3,623       682,338       136,059       822,020  
                               
Operating expenses   2,655,107       3,146,514       216,516       6,018,137  
                               
Loss from operations $ (2,651,484 )   $ (2,464,176 )   $ (80,457 )   $ (5,196,117 )